<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage - Salati, JA - 2019 | Cochrane Library</title> <meta content="Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage - Salati, JA - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001808.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage - Salati, JA - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001808.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001808.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage" name="citation_title"/> <meta content="Jennifer A Salati" name="citation_author"/> <meta content="Oregon Health and Science University" name="citation_author_institution"/> <meta content="Sebastian J Leathersich" name="citation_author"/> <meta content="King Edward Memorial Hospital for Women" name="citation_author_institution"/> <meta content="Myfanwy J Williams" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Anna Cuthbert" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Jorge E Tolosa" name="citation_author"/> <meta content="tolosaj@ohsu.edu" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD001808.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/04/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001808.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001808.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001808.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Blood Transfusion [statistics &amp; numerical data]; Delivery, Obstetric; *Labor Stage, Third; Odds Ratio; Oxytocin [*administration &amp; dosage]; Postpartum Hemorrhage [*prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001808.pub3&amp;doi=10.1002/14651858.CD001808.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001808\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001808\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","ms","ja","fr","th","hr","fa","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001808.pub3",title:"Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage",firstPublishedDate:"Apr 29, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001808.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001808.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001808.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001808.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001808.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001808.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001808.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001808.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001808.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001808.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>28882 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001808.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-sec-0132"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-sec-0084"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-sec-0120"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/appendices#CD001808-sec-0137"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/table_n/CD001808StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/table_n/CD001808StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information#CD001808-cr-0002">Jennifer A Salati</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information#CD001808-cr-0003">Sebastian J Leathersich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information#CD001808-cr-0004">Myfanwy J Williams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information#CD001808-cr-0005">Anna Cuthbert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information#CD001808-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Jorge E Tolosa</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information/en#CD001808-sec-0149">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 April 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001808.pub3">https://doi.org/10.1002/14651858.CD001808.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001808-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001808-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001808-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001808-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001808-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD001808-abs-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001808-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001808-abs-0001" lang="en"> <section id="CD001808-sec-0001"> <h3 class="title" id="CD001808-sec-0001">Background</h3> <p>Active management of the third stage of labour reduces the risk of postpartum blood loss (postpartum haemorrhage (PPH)), and is defined as administration of a prophylactic uterotonic, early umbilical cord clamping and controlled cord traction to facilitate placental delivery. The choice of uterotonic varies across the globe and may have an impact on maternal outcomes. This is an update of a review first published in 2001 and last updated in 2013. </p> </section> <section id="CD001808-sec-0002"> <h3 class="title" id="CD001808-sec-0002">Objectives</h3> <p>To determine the effectiveness of prophylactic oxytocin to prevent PPH and other adverse maternal outcomes in the third stage of labour. </p> </section> <section id="CD001808-sec-0003"> <h3 class="title" id="CD001808-sec-0003">Search methods</h3> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) (6 March 2019) and reference lists of retrieved studies. </p> </section> <section id="CD001808-sec-0004"> <h3 class="title" id="CD001808-sec-0004">Selection criteria</h3> <p>Randomised, quasi‐ or cluster‐randomised trials including women undergoing vaginal delivery who received prophylactic oxytocin during management of the third stage of labour. Primary outcomes were blood loss 500 mL or more after delivery, need for additional uterotonics, and maternal all‐cause mortality. </p> </section> <section id="CD001808-sec-0005"> <h3 class="title" id="CD001808-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion, extracted data, and assessed trial quality. Data were checked for accuracy. We assessed the quality of the evidence using the GRADE approach. </p> </section> <section id="CD001808-sec-0006"> <h3 class="title" id="CD001808-sec-0006">Main results</h3> <p>This review includes 24 trials, with 23 trials involving 10,018 women contributing data. Due to many trials assessed at high risk of bias, evidence grade ranged from very low to moderate quality<i>.</i> </p> <p><b>Prophylactic oxytocin versus no uterotonics or placebo (nine trials)</b> <br/> Prophylactic oxytocin compared with no uterotonics or placebo may reduce the risk of blood loss of 500 mL after delivery (average risk ratio (RR) 0.51, 95% confidence interval (C) 0.37 to 0.72; 4162 women; 6 studies; Tau² = 0.10, I² = 75%; low‐quality evidence), and blood loss 1000 mL after delivery (RR 0.59, 95% CI 0.42 to 0.83; 4123 women; 5 studies; low‐quality evidence). Prophylactic oxytocin probably reduces the need for additional uterotonics (average RR 0.54, 95% CI 0.36 to 0.80; 3135 women; 4 studies; Tau² = 0.07, I² = 44%; moderate‐quality evidence). There may be no difference in the risk of needing a blood transfusion in women receiving oxytocin compared to no uterotonics or placebo (RR 0.88, 95% CI 0.44 to 1.78; 3081 women; 3 studies; low‐quality evidence). Oxytocin may be associated with an increased risk of a third stage greater than 30 minutes (RR 2.55, 95% CI 0.88 to 7.44; 1947 women; 1 study; moderate‐quality evidence), however the confidence interval is wide and includes 1.0, indicating that there may be little or no difference.<br/> <br/> <b>Prophylactic oxytocin versus ergot alkaloids (15 trials)</b> </p> <p>It is uncertain whether oxytocin reduces the likelihood of blood loss 500 mL (average RR 0.84, 95% CI 0.56 to 1.25; 3082 women; 10 studies; Tau² = 0.14, I² = 49%; very low‐quality evidence) or the need for additional uterotonics compared to ergot alkaloids (average RR 0.89, 95% CI 0.43 to 1.81; 2178 women; 8 studies; Tau² = 0.76, I² = 79%; very low‐quality evidence), because the quality of this evidence is very low. The quality of evidence was very low for blood loss of 1000 mL (RR 1.13, 95% CI 0.63 to 2.01; 1577 women; 3 studies; very low‐quality evidence), and need for blood transfusion (average RR 1.37, 95% CI 0.34 to 5.51; 1578 women; 7 studies; Tau² = 1.34, I² = 45%; very low‐quality evidence), making benefit of oxytocin over ergot alkaloids uncertain. Oxytocin probably increases the risk of a prolonged third stage greater than 30 minutes (RR 4.69, 95% CI 1.63 to 13.45; 450 women; 2 studies; moderate‐quality evidence), although it is uncertain if this translates into increased risk of manual placental removal (average RR 1.10, 95% CI 0.39 to 3.10; 3127 women; 8 studies; Tau² = 1.07, I² = 76%; very low‐quality evidence). Oxytocin may make little or no difference to risk of diastolic blood pressure &gt; 100 mm Hg (average RR 0.28, 95% CI 0.04 to 2.05; 960 women; 3 studies; Tau² = 1.23, I² = 50%; low‐quality evidence), and is probably associated with a lower risk of vomiting (RR 0.09, 95% CI 0.05 to 0.14; 1991 women; 7 studies; moderate‐quality evidence), although the impact of oxytocin on headaches is uncertain (average RR 0.19, 95% CI 0.03 to 1.02; 1543 women; 5 studies; Tau² = 2.54, I² = 72%; very low‐quality evidence). </p> <p><b>Prophylactic oxytocin‐ergometrine versus ergot alkaloids (four trials)</b><br/> Oxytocin‐ergometrine may slightly reduce the risk of blood loss greater than 500 mL after delivery compared to ergot alkaloids (RR 0.44, 95% CI 0.20 to 0.94; 1168 women; 3 studies; low‐quality evidence), based on outcomes from quasi‐randomised trials with a high risk of bias. There were no maternal deaths reported in either treatment group in the one trial that reported this outcome (RR not estimable; 1 trial, 807 women; moderate‐quality evidence). Need for additional uterotonics was not reported. </p> <p>No subgroup differences were observed between active or expectant management, or different routes or doses of oxytocin for any of our comparisons. </p> </section> <section id="CD001808-sec-0007"> <h3 class="title" id="CD001808-sec-0007">Authors' conclusions</h3> <p>Prophylactic oxytocin compared with no uterotonics may reduce blood loss and the need for additional uterotonics. The effect of oxytocin compared to ergot alkaloids is uncertain with regards to blood loss, need for additional uterotonics, and blood transfusion. Oxytocin may increase the risk of a prolonged third stage compared to ergot alkaloids, although whether this translates into increased risk of manual placental removal is uncertain. This potential risk must be weighed against the possible increased risk of side effects associated with ergot alkaloids. Oxytocin‐ergometrine may reduce blood loss compared to ergot alkaloids, however the certainty of this conclusion is low. More high‐quality trials are needed to assess optimal dosing and route of oxytocin administration, with inclusion of important outcomes such as maternal mortality, shock, and transfer to a higher level of care. A network meta‐analysis of uterotonics for PPH prevention plans to address issues around optimal dosing and routes of oxytocin and other uterotonics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001808-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001808-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001808-abs-0019">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001808-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001808-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001808-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001808-abs-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001808-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001808-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD001808-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001808-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001808-abs-0015">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001808-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001808-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001808-abs-0005" lang="en"> <h3>Oxytocin to prevent excessive blood loss for women during the third stage of labour</h3> <p><b>What is the issue?</b> </p> <p>Active management of the third stage of labour (AMTSL) has been shown to decrease the risk of excessive blood loss after delivery. This management strategy has been defined as administration of a medication to increase uterine tone and contractions, early umbilical cord clamping and gentle cord traction to facilitate placental delivery. While AMTSL has become standard practice in many countries and institutions, execution of the individual components varies. Oxytocin is a uterotonic medication that promotes increased uterine tone and contractions, and is commonly administered immediately following delivery of the infant's shoulder as part of AMTSL. This review considers the efficacy and safety of oxytocin prophylaxis in the third stage of labour compared with no uterotonics, a placebo, ergot alkaloids, and in combination with ergometrine compared with ergot alkaloids. </p> <p><b>Why is this important?</b> </p> <p>Postpartum haemorrhage is one of the most prevalent causes of maternal morbidity and mortality worldwide, therefore, determining the most effective preventative strategies is crucial. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for evidence in March 2019 and identified six trials that met the inclusion criteria for the review. Outcomes from an additional 1100 women from these six trials was combined with those from the previous version of this review for a total of 10,018 women (23 trials). Of note, two previously included trials were excluded from this current review due to methodological concerns.<br/> The majority of trials contributing information to this review were found to be at high risk of bias. The quality of evidence ranged from very low to moderate, and for most outcomes was assessed as low to very low quality. </p> <p>Our results showed that compared to no uterotonics or placebo, oxytocin may reduce the risk of blood loss (quality of evidence: low) and the need for additional uterotonics (quality of evidence: moderate). The effect of oxytocin compared with ergot alkaloids is uncertain with regards to blood loss (quality of evidence: very low), need for additional uterotonics (quality of evidence: very low), and need for blood transfusion (quality of evidence: very low), but may increase the risk of a third stage greater than 30 minutes (quality of evidence: moderate). Whether or not this translates into increased risk of needing a manual placental removal is uncertain (quality of evidence: very low). This potential risk of retained placenta must be weighed against a possible increased risk of side effects with ergot alkaloids, including diastolic hypertension (quality of evidence: low), vomiting (quality of evidence: very low), and headaches (quality of evidence: very low). While the combination of oxytocin and ergometrine may slightly reduce the risk of blood loss compared to ergot alkaloids (quality of evidence: low), the certainty of this conclusion is low given the poor quality of contributing studies. </p> <p><b>What does this mean?</b> </p> <p>Oxytocin may reduce blood loss and the need for additional uterotonics when given prophylactically in the third stage of labour, and therefore could be considered as a component of AMTSL. The side‐effect profile may be more favourable than ergot alkaloids, which must be weighed against a possible increased risk of third stage greater than 30 minutes and unclear benefit of oxytocin or ergot alkaloids with regards to blood loss.<br/> <br/> More placebo‐controlled, randomised, double‐blinded trials are needed to improve the quality of data used to compare oxytocin versus ergot alkaloids. Future studies should aim to include important outcomes such as maternal mortality, shock, transfer to a higher level of care, serious side effects, and other patient‐centred outcomes. A large complex review analysing all available data from different uterotonic medications (network meta‐analysis) will help to inform future choice of uterotonic and the best route and dose of administration. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001808-sec-0132" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001808-sec-0132"></div> <h3 class="title" id="CD001808-sec-0133">Implications for practice</h3> <section id="CD001808-sec-0133"> <p>Prophylactic oxytocin may reduce the risk of blood loss and decrease the need for additional uterotonics, and could be considered as a component of the active management of the third stage of labour (AMTSL). It is unclear whether prophylactic oxytocin reduces postpartum blood loss compared to ergot alkaloids, however it may be associated with fewer side effects. This must be weighed against a possible increased risk of a third stage greater than 30 minutes, although whether or not this translates into greater need for manual placental removal is uncertain given the low quality of the evidence. The combination of oxytocin and ergometrine may slightly reduce the risk of postpartum blood loss compared to ergot alkaloids, however the certainty of this conclusion is low given the lack of randomised trials and imprecision. </p> </section> <h3 class="title" id="CD001808-sec-0134">Implications for research</h3> <section id="CD001808-sec-0134"> <p>The majority of evidence for outcomes in this review was of low quality, with many trials deemed at high risk of bias due to lack of blinding, concerns regarding allocation concealment, as well as quasi‐randomisation. More high‐quality randomised controlled trials with adequate blinding of participants and use of gravimetric techniques for blood loss measurement, are needed. High‐quality randomised controlled trials examining oxytocin dosing and route of administration, as well as oxytocin in comparison to other available regimens will be important in determining optimal management of the third stage of labour. Additionally, future trials should examine a range of outcomes that include, not only outcomes directly related to blood loss and side effects, but include those outcomes that have been recommended as part of a core outcome set for reporting in postpartum haemorrhage (PPH) prevention studies (<a href="./references#CD001808-bbs2-0091" title="MeherS , CuthbertA , KirkhamJJ , WilliamsonP , AbalosE , AflaifelN , et al. Core outcome sets for prevention and treatment of postpartum hemorrhage: an international Delphi consensus study. British Journal of Obstetrics and Gynaecology2018;126(1):83‐93. [DOI: 10.1111/1471‐0528.15335] ">Meher 2018</a>). Such outcomes include maternal mortality (all‐cause and from causes other than bleeding), shock, transfer to a higher level of care, patient‐reported outcomes (maternal satisfaction with therapy and quality of life) and neonatal outcomes (breastfeeding). A network meta‐analysis of uterotonics for PPH prevention plans to address issues around optimal dosing and routes of oxytocin and other uterotonics. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001808-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001808-sec-0043"></div> <div class="table" id="CD001808-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxytocin compared to no uterotonics or placebo for the third stage of labour to prevent postpartum haemorrhage</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oxytocin compared to no uterotonics or placebo for the third stage of labour to prevent postpartum haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Setting:</b> hospital labour wards and home births in France, Germany, the Netherlands, Sweden, South Africa, Tunisia, and the UK<br/> <b>Intervention:</b> oxytocin<br/> <b>Comparison:</b> no uterotonics or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no uterotonics</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oxytocin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 500 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/> (0.37 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4162<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000<br/> (89 to 172) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Need for additional uterotonics</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/> (0.36 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3135<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (41 to 91) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal all‐cause mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 1000 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/> (0.42 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4123<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (20 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.44 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3081<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (5 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Third stage greater than 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.55<br/> (0.88 to 7.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1947<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (5 to 45) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Lack of blinding in the majority of trials raises concern for biased outcome assessment as most trials utilised visual estimation of blood loss (risk of bias ‐1) </p> <p><sup>2</sup> Large variations in effect and non‐overlapping 95% confidence intervals; I<sup>2</sup> = 75% indicating substantial heterogeneity (inconsistency ‐1) </p> <p><sup>3</sup> Lack of participant blinding in some trials may bias decisions to administer additional uterotonics (risk of bias ‐1) </p> <p><sup>4</sup> Few events and wide 95% confidence intervals (imprecision ‐1) </p> <p><sup>5</sup> Lack of personnel blinding may bias decisions to administer blood transfusions (risk of bias ‐1) </p> <p><sup>6</sup> Wide 95% confidence intervals including line of no effect (imprecision ‐1) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001808-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oxytocin compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oxytocin compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Setting:</b> hospital labour wards and home births in the Netherlands, Sweden, South Africa, Japan, Singapore, India, Nepal, Tunisia, Nigeria, New Zealand, the UK and the USA<br/> <b>Intervention:</b> oxytocin<br/> <b>Comparison:</b> ergot alkaloids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ergot alkaloids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oxytocin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 500 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.56 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3082<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>116 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/> (65 to 145) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Need for additional uterotonics</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.43 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2178<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000<br/> (40 to 170) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal all‐cause mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 1000 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.63 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1577<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/> (20 to 64) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/> (0.34 to 5.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1578<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (4 to 71) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Third stage &gt; 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.69<br/> (1.63 to 13.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>450<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000<br/> (29 to 240) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.28<br/> (0.04 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>960<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (2 to 90) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Studies with serious methodological limitations in multiple domains (risk of bias ‐2) </p> <p><sup>2</sup> Wide 95% confidence intervals including line of no effect (imprecision ‐1) </p> <p><sup>3</sup> Studies with serious methodological limitations (risk of bias ‐1) </p> <p><sup>4</sup> Large variations in effect and non‐overlapping 95% confidence intervals; I<sup>2</sup> = 79% indicating substantial heterogeneity (inconsistency ‐1) </p> <p><sup>5</sup> Large variations in effect; I<sup>2</sup> = 45% indicating substantial heterogeneity (inconsistency ‐1) </p> <p><sup>6</sup> Wide 95% confidence intervals including line of no effect, and few events (imprecision ‐1) </p> <p><sup>7</sup> Wide 95% confidence interval and few events, including one study with no events (imprecision ‐1) </p> <p><sup>8</sup> Unclear allocation concealment in majority of studies (risk of bias ‐1) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001808-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oxytocin + ergometrine compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oxytocin + ergometrine compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Setting:</b> hospital labour wards in Sweden, Singapore, Tunisia, and the UK<br/> <b>Intervention:</b> oxytocin + ergometrine<br/> <b>Comparison:</b> ergot alkaloids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ergot alkaloids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oxytocin + ergometrine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 500 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44<br/> (0.20 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1168<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (7 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Need for additional uterotonics</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal all‐cause mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>807<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It was not possible to obtain effect estimates as there were no events reported.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 1000 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Third stage &gt; 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Lack of blinding of estimated outcome assessment, and concern regarding randomisation methods (risk of bias ‐1) </p> <p><sup>2</sup> Few events and wide 95% confidence intervals (imprecision ‐1) </p> <p><sup>3</sup> No events reported for this outcome (imprecision ‐1) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001808-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001808-sec-0044"></div> <section id="CD001808-sec-0045"> <h3 class="title" id="CD001808-sec-0045">Description of the condition</h3> <p>The third stage of labour is defined as the time from the birth of the baby to expulsion of the placenta. Following delivery of the baby, the uterine muscle contracts, resulting in gradual placental separation and expulsion as well as contraction of uterine muscle around maternal vessels within the placental bed. Activation of the maternal coagulation system occurs in tandem. The degree of blood loss following delivery is most directly related to how quickly and efficiently these processes occur.<br/> <br/> Postpartum haemorrhage (PPH) has commonly been defined by the World Health Organization (WHO) and other expert authorities as blood loss of 500 mL or more from the genital tract within 24 hours of birth (<a href="./references#CD001808-bbs2-0080" title="Borovac‐PinheiroA , PacagnellaRC , CecattiJG , MillerS , ElAyadiAM , SouzaJP , et al. Postpartum hemorrhage: new insights for definition and diagnosis. American Journal of Obstetrics and Gynecology2018;219(2):162‐8. ">Borovac‐Pinheiro 2018</a>; <a href="./references#CD001808-bbs2-0104" title="World Health Organization. WHO recommendations for the prevention of postpartum haemorrhage. https://afro.who.int/sites/default/files/2017‐06/WHO_MPS_0706_engPPH.pdf. Geneva: World Health Organization, (accessed 1 February 2019). ">WHO 2018</a>). However, there is currently no single definition for PPH that has been agreed upon internationally, and multiple guidelines and definitions exist (<a href="./references#CD001808-bbs2-0080" title="Borovac‐PinheiroA , PacagnellaRC , CecattiJG , MillerS , ElAyadiAM , SouzaJP , et al. Postpartum hemorrhage: new insights for definition and diagnosis. American Journal of Obstetrics and Gynecology2018;219(2):162‐8. ">Borovac‐Pinheiro 2018</a>). A significant issue complicating the use of blood loss thresholds to define PPH is the challenge surrounding quantification of blood loss. Visual estimation has historically been standard practice, but has been shown to lead to underestimation of large volume blood loss by up to 30% to 50%, and overestimation of small volume blood loss regardless of level of training (<a href="./references#CD001808-bbs2-0082" title="DildyGA , PaineAR , GeorgeNC , VelascoC . Estimating blood loss: can teaching significantly improve visual estimation?. Obstetrics and Gynecology2004;104(3):601‐6. ">Dildy 2004</a>; <a href="./references#CD001808-bbs2-0088" title="HoganMC , ForemanKJ , NaghaviM , AhnSY , WangM , MakelaSM , et al. Maternal mortality of 181 countries, 1980‐2008: a systemic analysis of progress towards Millennium Development Goals 5. Lancet2010;375(9726):1609‐23. ">Hogan 2010</a>; <a href="./references#CD001808-bbs2-0099" title="StaffordI , DildyGA , ClarkSL , BelfortMA . Visually estimated and calculated blood loss in vaginal and cesarean delivery. American Journal of Obstetrics and Gynecology2008;199(5):519.e1‐7. ">Stafford 2008</a>). Gravimetric methods of quantification, such as calibrated drapes and weighing of pads, may be more accurate and are being increasingly adopted by obstetric centres (<a href="./references#CD001808-bbs2-0078" title="Al KadriHM , Al AnaziBK , TamimHM . Visual estimation versus gravimetric measurement of postpartum blood loss: a prospective cohort study. Archives of Gynecology and Obstetrics2011;283(6):1207‐13. ">Al Kadri 2011</a>; <a href="./references#CD001808-bbs2-0101" title="ToledoP , McCarthyRJ , HewlettBJ , FitzgeraldPC , WongCA . The accuracy of blood loss estimation after simulated vaginal delivery. Anesthesia Analgesia2007;105(6):1736‐40. ">Toledo 2007</a>).<br/> <br/> The impact of any amount of blood loss for an individual woman may be modified by her overall health status, underlying medical conditions, haemodynamic status and access to healthcare resources. Women experiencing excessive blood loss after delivery are at increased risk of significant complications including the need for blood transfusion, hysterectomy and loss of fertility, prolonged hospitalisation, transfer to the intensive care unit, shock, and multi‐organ failure. </p> </section> <section id="CD001808-sec-0046"> <h3 class="title" id="CD001808-sec-0046">Description of the intervention</h3> <p>Techniques to prevent PPH may target any aspect of the third stage of labour. A recent review determined that active management of the third stage of labour (AMTSL), defined as prophylactic administration of a uterotonic, early umbilical cord clamping and controlled cord traction, decreases the risk of blood loss greater than 1000 mL (<a href="./references#CD001808-bbs2-0079" title="BegleyCM , GyteGML , DevaneD , McGuireW , WeeksA , BiestyLM . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2019, Issue 2. [DOI: 10.1002/14651858.CD007412.pub5] ">Begley 2019</a>), although the evidence was found to be of very low quality. While AMTSL is recommended by many organisations and has become standard practice in most obstetric centres, performance of individual components varies. Based on recent evaluations of individual components of the AMTSL, the WHO regards controlled cord traction as optional, routine early cord clamping as generally contraindicated, and uterotonics as the main intervention that should be offered to all women in the third stage of labour (<a href="./references#CD001808-bbs2-0103" title="World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. https://apps.who.int/iris/bitstream/handle/10665/75411/9789241548502_eng.pdf;sequence=1. Geneva: World Health Organization, (date accessed 27 August 2018). ">WHO 2012</a>). The WHO and other authorities currently consider oxytocin to be the uterotonic of choice (<a href="./references#CD001808-bbs2-0104" title="World Health Organization. WHO recommendations for the prevention of postpartum haemorrhage. https://afro.who.int/sites/default/files/2017‐06/WHO_MPS_0706_engPPH.pdf. Geneva: World Health Organization, (accessed 1 February 2019). ">WHO 2018</a>). Of note, a recent network meta‐analysis examined the effectiveness and side effects of multiple uterotonic agents (<a href="./references#CD001808-bbs2-0085" title="GallosID , PapadopoulouA , ManR , AthanasopoulosN , TobiasA , PriceMJ , et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 12. [DOI: 10.1002/14651858.CD011689.pub3] ">Gallos 2018</a>). They concluded that all uterotonics were effective for preventing PPH, but that ergometrine‐oxytocin and misoprostol plus oxytocin might be more efficacious than oxytocin alone, at the expense of a greater risk of side effects. They also concluded that carbetocin may be more effective than oxytocin without an increase in side effects. </p> <p>Oxytocin is a naturally occurring uterotonic, and first became available for use in 1953 (<a href="./references#CD001808-bbs2-0083" title="Du VigneaudV , ResslerC , TippetS . The sequence of amino acids in oxytocin with a proposal for the structure of oxytocin. Journal of Biological Chemistry1953;205:949. ">Du Vigneaud 1953</a>). Oxytocin binds to receptors within the myometrium to facilitate frequent and prolonged uterine contractions within minutes, with a short half‐life of two to four minutes. It may be administered intravenously (IV, typically diluted in an infusion) or intramuscularly (IM). When given in high volumes it may result in an anti‐diuretic effect leading to hyponatraemia, headache, vomiting, drowsiness or convulsions. It can be stored at room temperature for a limited period of time, although long‐term storage is recommended in the dark at four to eight degrees Celsius.<br/> <br/> Ergometrine was discovered as the uterotonic component of ergot in 1932 (<a href="./references#CD001808-bbs2-0092" title="MoirJC . The action of ergot preparation on the puerperal uterus. British Medical Journal1932;1:1119‐22. ">Moir 1932</a>). It became popular for routine management of PPH in the early 1950s (<a href="./references#CD001808-bbs2-0093" title="MoirJC . The history of present day use of ergot. Canadian Medical Association Journal1955;72:727‐34. ">Moir 1955</a>). Methylergometrine and ergometrine are the most commonly used ergot alkaloids. They bind to adrenergic myometrial receptors and increase uterine tone, leading to frequent and then sustained uterine contractions. The onset of action is rapid, within two to 10 minutes, with a half‐life of approximately three hours. They are most commonly administered by the IM or oral route, but can be given IV. Side effects include hypertension, nausea and emesis, and other side effects related to vasoconstriction of vascular smooth muscle. To prevent rapid deterioration, formulations need to be stored in the dark at four to eight degrees Celsius; ergot alkaloids are more unstable at room temperature and with light exposure than oxytocin.<br/> <br/> A combination of ergometrine and oxytocin (Syntometrine) was synthesised in 1963 (<a href="./references#CD001808-bbs2-0084" title="EmbreyMP , BarberDT , ScudamoreJH . Use of syntometrine in prevention of post partum haemorrhage. British Medical Journal1963;1:1387‐9. ">Embrey 1963</a>). Syntometrine is comprised of oxytocin 5 international units (IU) and ergometrine 0.5 mg, and is typically given IM although can be given IV. The pharmacologic properties reflect those of its individual components. It is available in some countries, although not currently available in the USA. </p> </section> <section id="CD001808-sec-0047"> <h3 class="title" id="CD001808-sec-0047">How the intervention might work</h3> <p>Uterotonic drugs increase the tone of the uterine muscles, resulting in uterine contractions. These contractions produce shearing forces that aid in placental separation, and also result in myometrial contraction around the involuting placental bed. After placental separation, expulsion is assisted by continued contractions. By enhancing these mechanisms, uterotonics facilitate rapid placental delivery and contribute to minimising blood loss in the third stage. </p> </section> <section id="CD001808-sec-0048"> <h3 class="title" id="CD001808-sec-0048">Why it is important to do this review</h3> <p>Haemorrhage during childbirth is the leading cause of maternal mortality worldwide, accounting for approximately 25% of maternal deaths, or over half a million women in mostly low‐ and middle‐income countries (<a href="./references#CD001808-bbs2-0098" title="SayL , ChouD , GemmillA , TuncalpO , MollerA , DanielsJ , et al. Global cause of maternal death: a WHO systematic analysis. Lancet2014;2(6):e323‐e333. ">Say 2014</a>). PPH accounts for a greater proportion of maternal deaths in countries with a low sociodemographic index (46%) compared to countries with a high sociodemographic index (9%), reflecting a combination of issues including variations in quality and access to care, and population risk factors (<a href="./references#CD001808-bbs2-0089" title="KassebaumNJ , BarberRM , BhuttaZA , DandonaL , GethingPW , HaySI , et al. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet2016;388(10053):1775‐812. ">Kassebaum 2016</a>; <a href="./references#CD001808-bbs2-0098" title="SayL , ChouD , GemmillA , TuncalpO , MollerA , DanielsJ , et al. Global cause of maternal death: a WHO systematic analysis. Lancet2014;2(6):e323‐e333. ">Say 2014</a>). Continuing efforts to determine the most effective PPH prevention strategies are necessary to improve maternal health worldwide.<br/> <br/> The last version of this Cochrane Review of the prophylactic use of oxytocin for preventing PPH was in 2013. This updated review is needed to inform updated guidelines from the WHO on prevention of PPH, and adds to existing Cochrane systematic reviews examining the use of various medications as prophylaxis in the third stage of labour (<a href="./references#CD001808-bbs2-0085" title="GallosID , PapadopoulouA , ManR , AthanasopoulosN , TobiasA , PriceMJ , et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 12. [DOI: 10.1002/14651858.CD011689.pub3] ">Gallos 2018</a>, <a href="./references#CD001808-bbs2-0090" title="LiabsuetrakulT , ChoobunT , PeeyananjarassriK , IslamQM . Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database of Systematic Reviews2018, Issue 6. [DOI: 10.1002/14651858.CD005456.pub3] ">Liabsuetrakul 2018</a>; <a href="./references#CD001808-bbs2-0095" title="NovikovaN , HofmeyrGJ , CluverC . Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD007872.pub3] ">Novikova 2015</a>; <a href="./references#CD001808-bbs2-0102" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001808-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001808-sec-0049"></div> <p>To determine the effectiveness of prophylactic oxytocin to prevent postpartum haemorrhage (PPH) and other adverse maternal outcomes in the third stage of labour. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001808-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001808-sec-0050"></div> <section id="CD001808-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001808-sec-0052"> <h4 class="title">Types of studies</h4> <p>All randomised, cluster‐ or quasi‐randomised controlled trials comparing prophylactic oxytocin with another uterotonic (ergot alkaloids) or no uterotonic/placebo for the management of the third stage of labour were considered for inclusion. Studies reported as abstracts have not been included if there was insufficient information for data extraction and 'Risk of bias' assessment. </p> </section> <section id="CD001808-sec-0053"> <h4 class="title">Types of participants</h4> <p>All trials including pregnant women anticipating a vaginal delivery were considered. Studies where participants received the prophylactic uterotonic after delivery of the placenta were excluded. </p> </section> <section id="CD001808-sec-0054"> <h4 class="title">Types of interventions</h4> <p>The purpose of this review is to compare three interventions:</p> <p> <ol id="CD001808-list-0001"> <li> <p>use of prophylactic oxytocin at any dose for the third stage of labour versus no uterotonics or placebo; </p> </li> <li> <p>use of prophylactic oxytocin at any dose for the third stage of labour versus ergot alkaloids; </p> </li> <li> <p>use of prophylactic oxytocin‐ergometrine (Synometrine) versus ergot alkaloids.</p> </li> </ol> </p> <p>The current review concentrates on oxytocin given by injection into a maternal vein (IV) or muscle (IM). Other uterotonic agents administered to the mother by IV or IM are addressed in <a href="./references#CD001808-bbs2-0085" title="GallosID , PapadopoulouA , ManR , AthanasopoulosN , TobiasA , PriceMJ , et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 12. [DOI: 10.1002/14651858.CD011689.pub3] ">Gallos 2018</a> (all uterotonics) and <a href="./references#CD001808-bbs2-0100" title="SuLL , ChongYS , SamuelM . Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD005457.pub4] ">Su 2012</a> (carbetocin, oxytocin and oxytocin‐ergometrine). The role of prophylactic prostaglandins or ergot alkaloids and uterotonics given through the umbilical vein, for the treatment of blood loss or retained placenta, are the subjects of other reviews and were not included here (<a href="./references#CD001808-bbs2-0090" title="LiabsuetrakulT , ChoobunT , PeeyananjarassriK , IslamQM . Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database of Systematic Reviews2018, Issue 6. [DOI: 10.1002/14651858.CD005456.pub3] ">Liabsuetrakul 2018</a>; <a href="./references#CD001808-bbs2-0094" title="MoriR , NardinJM , YamamotoN , CarroliG , WeeksA . Umbilical vein injection for the routine management of third stage of labour. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD006176.pub2] ">Mori 2012</a>; <a href="./references#CD001808-bbs2-0102" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>). Similarly, endogenous oxytocin (nipple stimulation) is not included in this review. </p> </section> <section id="CD001808-sec-0055"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes noted with an asterisk are core prevention of PPH outcomes. Outcomes in bold text are the main outcomes that were assessed using the GRADE approach. </p> <section id="CD001808-sec-0056"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001808-list-0002"> <li> <p><b>Blood loss 500 mL or more after delivery*</b> </p> </li> <li> <p><b>Need for additional uterotonics*</b> </p> </li> <li> <p><b>Maternal all‐cause mortalit</b>y </p> </li> </ol> </p> </section> <section id="CD001808-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001808-list-0003"> <li> <p><b>Blood loss 1000 mL or more after delivery*</b> </p> </li> <li> <p><b>Blood transfusion</b> </p> </li> <li> <p><b>Third stage greater than 30 minutes</b> </p> </li> <li> <p><b>Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward</b> </p> </li> <li> <p>Mean blood loss (mL)</p> </li> <li> <p>Maternal haemoglobin (Hb) &lt; 7 g/dL 24 to 48 hours postpartum</p> </li> <li> <p>Mean length of third stage (minutes)</p> </li> <li> <p>Manual removal of the placenta</p> </li> <li> <p>Vomiting between delivery of the baby and discharge from the labour ward*</p> </li> <li> <p>Headache between delivery of the baby and discharge from the labour ward*</p> </li> <li> <p>Shock*</p> </li> <li> <p>Transfer to a higher level of care*</p> </li> <li> <p>Mortality from causes other than bleeding</p> </li> <li> <p>Maternal satisfaction with therapy*</p> </li> <li> <p>Quality of life*</p> </li> <li> <p>Breastfeeding</p> </li> </ol> </p> </section> </section> </section> <section id="CD001808-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <p>The following search methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD001808-sec-0059"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (6 March 2019).<br/> <br/> The Register is a database containing over 25,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this <a href="https://pregnancy.cochrane.org/pregnancy-and-childbirth-groups-trials-register" target="_blank">link</a>. </p> <p>Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD001808-list-0004"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD001808-bbs1-0001" title="">Included studies</a>; <a href="./references#CD001808-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD001808-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD001808-bbs1-0004" title="">Ongoing studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) for unpublished, planned and ongoing trial reports (6 March 2019) using the search methods described in <a href="./appendices#CD001808-sec-0138">Appendix 1</a>. </p> </section> <section id="CD001808-sec-0060"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved studies.</p> <p>We did not apply any language or date restrictions.</p> </section> </section> <section id="CD001808-sec-0061"> <h3 class="title" id="CD001808-sec-0061">Data collection and analysis</h3> <p>For methods used in the previous version of this review, <i>see</i><a href="./references#CD001808-bbs2-0109" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>. </p> <p>For this update, the following methods were used for assessing the reports that were identified as a result of the updated search. </p> <p>The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD001808-sec-0062"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third review author. </p> </section> <section id="CD001808-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data. For eligible studies, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted a third review author. Data were entered into Review Manager software (<a href="./references#CD001808-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and checked for accuracy. When information regarding any of the above was unclear, we planned to contact authors of the original reports to provide further details. </p> </section> <section id="CD001808-sec-0064"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001808-bbs2-0086" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Any disagreement was resolved by discussion or by involving a third assessor. </p> <section id="CD001808-sec-0065"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD001808-list-0005"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001808-sec-0066"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001808-list-0006"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001808-sec-0067"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001808-list-0007"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD001808-sec-0068"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD001808-list-0008"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001808-sec-0069"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re‐include missing data in the analyses which we undertook. </p> <p>We assessed methods as:</p> <p> <ul id="CD001808-list-0009"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001808-sec-0070"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD001808-list-0010"> <li> <p>low risk of bias (where it is clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD001808-sec-0071"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> </section> <section id="CD001808-sec-0072"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Handbook</i> (<a href="./references#CD001808-bbs2-0086" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). With reference to (1) to (6) above, we planned to assess the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. In future updates, we will explore the impact of the level of bias through undertaking sensitivity analyses ‐ <i>see</i><a href="#CD001808-sec-0083">Sensitivity analysis</a>. </p> </section> <section id="CD001808-sec-0073"> <h5 class="title">Assessment of the quality of the evidence using the GRADE approach</h5> <p>We assessed the quality of evidence using the GRADE approach as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a> in order to assess the quality of the body of evidence. Where data were available, we planned to use GRADE to assess the overall quality of the evidence for our main comparisons. </p> <p> <ol id="CD001808-list-0011"> <li> <p>Prophylactic oxytocin at any dose for the third stage of labour versus placebo.</p> </li> <li> <p>Prophylactic oxytocin at any dose for the third stage of labour versus ergot alkaloids.</p> </li> <li> <p>Prophylactic oxytocin‐ergometrine versus ergot alkaloids.</p> </li> </ol> </p> <p>We assessed the following outcomes.</p> <p> <ol id="CD001808-list-0012"> <li> <p>Blood loss 500 mL or more after delivery</p> </li> <li> <p>Need for additional uterotonics</p> </li> <li> <p>Maternal all‐cause mortality</p> </li> <li> <p>Blood loss 1000 mL or more after delivery</p> </li> <li> <p>Blood transfusion</p> </li> <li> <p>Third stage greater than 30 minutes</p> </li> <li> <p>Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward </p> </li> </ol> </p> <p>Grade outcomes are included in our review 'Summary of Findings' tables: <a href="./full#CD001808-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD001808-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001808-tbl-0003">summary of findings Table 3</a>.<br/> <br/> We used the <a href="http://www.guidelinedevelopment.org/" target="_blank">GRADEpro</a> Guideline Development Tool to import data from Review Manager 5.3 (<a href="./references#CD001808-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) in order to create ’Summary of findings’ tables. A summary of the intervention effect and a measure of quality for each of the above outcomes was be produced using the GRADE approach as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a>. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> <section id="CD001808-sec-0074"> <h4 class="title">Measures of treatment effect</h4> <section id="CD001808-sec-0075"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals. </p> </section> <section id="CD001808-sec-0076"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference if outcomes were measured in the same way between trials. In future, if necessary, we plan to use the standardised mean difference to combine trials that measure the same outcome, but use different methods. </p> </section> </section> <section id="CD001808-sec-0077"> <h4 class="title">Unit of analysis issues</h4> <p>There were no cluster‐randomised or cross‐over trials included in this review. Three of the included studies had more than two treatment groups (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). For these studies, we included each pair‐wise comparison separately, but divided shared groups approximately equally amongst the comparisons according to the <a href="http://handbook-5-1.cochrane.org" target="_blank">Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (section 16.5.4)</a>. </p> </section> <section id="CD001808-sec-0078"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, levels of attrition were noted. In future updates, if more eligible studies are included, the impact of including studies with high levels of missing data in the overall assessment of treatment effect will be explored by using sensitivity analysis.<br/> <br/> For all outcomes, analyses were carried out, as far as possible, on an intention‐to‐treat basis, i.e. we attempted to include all participants randomised to each group in the analyses. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD001808-sec-0079"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 40% and either the Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD001808-sec-0080"> <h4 class="title">Assessment of reporting biases</h4> <p>Meta‐analyses containing 10 or more studies were investigated using funnel plots to assess reporting bias. Funnel plot asymmetry was assessed visually. If asymmetry was suggested by a visual assessment, we considered exploratory analyses to investigate it where appropriate. </p> </section> <section id="CD001808-sec-0081"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager software (<a href="./references#CD001808-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and the trials’ populations and methods were judged sufficiently similar.<br/> <br/> If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary, if an average treatment effect across trials was considered clinically meaningful. The random‐effects summary was treated as the average of the range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. Where we used random‐effects analyses, the results were presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I². </p> </section> <section id="CD001808-sec-0082"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses. We considered whether an overall summary was meaningful, and if it was, used random‐effects analysis to produce it. </p> <p>We carried out the following subgroup analyses.</p> <p> <ol id="CD001808-list-0013"> <li> <p>Management of the third stage: use of oxytocin with or without active management of the third stage of labour (AMTSL) </p> </li> <li> <p>Route of administration: oxytocin given IV versus IM.</p> </li> <li> <p>Dose of administration: oxytocin at a dose of at least 10 IU versus less than 10 IU</p> </li> </ol> </p> <p>The following outcomes were used in subgroup analyses.</p> <p> <ol id="CD001808-list-0014"> <li> <p>Blood loss 500 mL or more after delivery</p> </li> <li> <p>Need for additional uterotonics</p> </li> <li> <p>Maternal all‐cause mortality</p> </li> </ol> </p> <p>We assessed subgroup differences by interaction tests available within RevMan (<a href="./references#CD001808-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We reported the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value. </p> </section> <section id="CD001808-sec-0083"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses to explore the effect of risk of bias assessed by concealment of allocation, high attrition rates, or both, with studies at high risk of bias for these domains being temporarily excluded from the analyses in order to assess whether this makes any difference to the overall result. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001808-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001808-sec-0084"></div> <section id="CD001808-sec-0085"> <h3 class="title">Description of studies</h3> <section id="CD001808-sec-0086"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD001808-fig-0001">Figure 1</a>.<br/> <br/> The updated search in March 2019 search retrieved 27 trial reports. Of the 27 trials, six met the inclusion criteria for the review, 10 were excluded (12 reports), four are awaiting further classification (five reports), and two trials are ongoing. We added two new reports to already excluded studies. We also reassessed and excluded two studies that were previously included because we assessed that they were not randomised. This updated review includes six new randomised trials, for a total of 23 trials included in the meta‐analyses. </p> <div class="figure" id="CD001808-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD001808-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD001808-sec-0087"> <h4 class="title">Included studies</h4> <section id="CD001808-sec-0088"> <h5 class="title">Methods and setting</h5> <p>This review includes 24 trials, with a total of 10,018 women participating in the 23 included randomised studies comparing oxytocin versus no uterotonics or placebo, oxytocin versus ergot alkaloids, or oxytocin and ergometrine versus ergot alkaloids. Seven of the 23 included trials were deemed to be quasi‐randomised (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>).<br/> <br/> This review includes trials from low‐, middle‐, and high‐income countries. Nearly all births were attended by midwives or physicians in birth centres or hospitals, although one trial included women who had a home birth attended by an independent midwife (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>). Trials were conducted in Egypt and South Africa (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>), Nepal (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>), India (<a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>), Tunisia (<a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>), and Nigeria (<a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>). The remainder of the trials were conducted in high‐income countries including France (<a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>), Germany (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>), Japan (<a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>), the Netherlands (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>), New Zealand (<a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>), Singapore (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>), Sweden (<a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>), the UK (<a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>), and the USA (<a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). </p> </section> <section id="CD001808-sec-0089"> <h5 class="title">Dates of study and sources of trial funding</h5> <p>The trial reports spanned 1956 to 2014. Dates of study were reported for most trials except in five trials where the dates were not explicitly stated (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). Sources of funding included the County Council and County Health Authority Research and Development Foundation in the County of Jamtland, Sweden (<a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>). Methergine was provided by Sandoz Pharmaceuticals (<a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>), and Sulprostone provided by Schering‐Plough B.V. (<a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>). Please see the table <a href="./references#CD001808-sec-0155" title="">Characteristics of included studies</a> for further details. </p> </section> <section id="CD001808-sec-0090"> <h5 class="title">Participants</h5> <p>All participants in this study delivered vaginally. Instrumental deliveries were exclusion criteria in many studies (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>), but not explicitly stated as exclusion criteria in the remaining studies. One study included only women with forceps or vacuum delivery (<a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>). Full‐term pregnancies were an inclusion criteria in six studies (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>), while two studies included women at a gestational age of 28 weeks or greater (<a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>). Gestational age criteria were not explicitly stated in the remainder of the studies. </p> <p>The majority of studies excluded women with multiple gestations (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>). Women who received oxytocin during the course of labour were excluded in six studies (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>). </p> <p>Many studies attempted to account for postpartum haemorrhage risk by excluding women with risk factors including grand multiparity (<a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>), history of postpartum haemorrhage (<a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>), and blood coagulation disorders (<a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>). Anticoagulation therapy was considered an exclusion criteria in four studies (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>). Several studies did not explicitly state exclusion criteria but excluded women with complications or factors associated with increased blood loss (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). See <a href="./references#CD001808-sec-0155" title="">Characteristics of included studies</a> for details. </p> </section> <section id="CD001808-sec-0091"> <h5 class="title">Interventions and comparisons</h5> <p>Nine trials compared oxytocin versus no uterotonics (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a> or placebo (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>). The oxytocin was administered immediately after delivery of either the baby or the anterior shoulder, and we excluded any trials where administration was given after placental delivery. Oxytocin was given IV (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>) and IM (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>), at doses ranging from 3 to 5 IU (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>) up to 10 IU (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>), with one trial not explicitly stating the medication dosage (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>). The comparison group varied amongst the trials, with some comparing oxytocin with expectant management (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>) or administration of a normal saline placebo (<a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>), and others comparing oxytocin with active management alone (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). <a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a> had three intervention groups where women received oxytocin, oxytocin with uterine massage, or uterine massage as part of active management alone. For our analysis we combined the first two groups into the oxytocin intervention group, which we felt was acceptable because other included trials applied active management including uterine massage to both intervention and placebo groups. </p> <p>Fifteen trials compared oxytocin with ergot alkaloids (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). Oxytocin was administered by IV in eight of the trials (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>), and by IM route in the remaining trials, at either 5 IU (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>) or 10 IU doses. Eight studies used ergometrine either orally (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>), IV (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>) or IM route (<a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>). The remaining studies used methylergometrine by IV (<a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>) or IM route (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>); all at a 0.2 mg dose. Doses of IV or IM ergometrine ranged from 0.2 mg (<a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>) to 0.5 mg (<a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>), with one study reporting a 0.4 mg oral dose (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>). One study did not report specific doses but described that all medications were given at “standard doses” (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>). Active management or at least one component of the active management of the third stage of labour (AMTSL) was applied to both treatment groups in the eight studies (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). One trial utilised expectant management of the third stage (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>), and the remaining six trials did not describe management of the third stage. </p> <p>There were four trials that compared the effects of oxytocin‐ergometrine versus ergot alkaloids (<a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). Oxytocin‐ergometrine was given by IM route at a dose of 0.5 mg of ergometrine and 5 IU of oxytocin in three studies (<a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>), although in one the study it was given IV at a “standard dose” (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>). Ergometrine 0.5 mg was given IM (<a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>) or IV (<a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). In one study, ergometrine was given IV at a “standard dose” (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>). Two trials described AMTSL (<a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>), while the remaining two trials did not specifically describe third stage management. </p> <p>One trial, <a href="https://archie.cochrane.org/sections/documents/view?version=z1310291221114699958255591424690%26format=REVMAN_GRAPHS#STD-Fugo-1958" target="_blank">Fugo 1958</a>, met the criteria for inclusion but no data from this trial were used because the protocol called for manual removal of the placenta at 10 minutes after delivery of the infant and we felt that the methodology of this trial had high risk of bias and was not translatable into clinical practice. </p> </section> <section id="CD001808-sec-0092"> <h5 class="title">Outcomes</h5> <p>A range of outcomes were reported in the included trials. Sixteen trials reported blood loss of 500 mL or more after delivery (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>), and seven trials reported blood loss of 1000 mL or more (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>). Mean blood loss was reported in 14 studies (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>).<br/> <br/> Blood loss was measured gravimetrically (calibrated drapes or other containers) in four studies (<a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>), and by pad weights in six studies (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>). Three studies used a combination of gravimetric assessment and pad weights (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>). Three studies described collection of the blood in drapes or bins but did not specifically describe how the blood loss amount was determined (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a> reported that blood loss was estimated by “adding to the measured quantity a figure for loss on linen and swabs used during the perineal repair,” implying a combination of gravimetric and visual estimation. The method of blood loss determination was not specifically described in the remaining studies two (<a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>).<br/> <br/> Several studies reported surrogate outcomes for significant blood loss including need for a blood transfusion (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>) and maternal haemoglobin (Hb) concentration &lt; 7 g/dL 24 to 48 hours postpartum (<a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>). The need for additional uterotonics was examined in 11 studies (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>).<br/> <br/> Many studies reported outcomes related to timing of placental delivery. A third stage of labour greater than 30 minutes was reported in three studies (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>), while others reported the mean length of the third stage (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>). The need for manual placental removal was reported in 14 trials (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>).<br/> <br/> Many studies examined maternal side effects, including elevated diastolic blood pressure (<a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>), headache (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>), and vomiting (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>).<br/> <br/> We included the important outcomes of maternal all‐cause mortality and mortality from causes other than bleeding in our study. Only <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a> reported the outcome of maternal mortality, however there were no events in either of the treatment groups. The remainder of the studies did not include maternal mortality as an outcome. Similarly, several other important outcomes were not reported in any of the trials, including incidence of shock, transfer to a higher level of care, maternal satisfaction with treatment, quality of life indices or breastfeeding outcomes. </p> </section> <section id="CD001808-sec-0093"> <h5 class="title">Trial author's declarations of interest</h5> <p>The authors from five trials reported no declarations of interest (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>), while this information was not reported in the remaining studies. </p> </section> </section> <section id="CD001808-sec-0094"> <h4 class="title">Excluded studies</h4> <p>The details of all excluded studies are outlined in the table <a href="./references#CD001808-sec-0156" title="">Characteristics of excluded studies</a>. In this updated version of the review, we excluded seven new studies. Six studies had comparison groups that were not in the scope of this review (<a href="./references#CD001808-bbs2-0039" title="JansS , HerschderferKC , vanDiemMT , AitinkM , RijndersM , van derPal‐BruinK , et al. LENTE study: effectiveness of prophylactic intramuscular oxytocin during third stage of labour amongst low risk women. A randomized controlled trial. 31st International Confederation of Midwives Triennial Congress. Midwives ‐ Making a Difference in the World; 2017 June 18‐22; Toronto, Canada. 2017:Abstract no: P1.063. ">Jans 2017</a>; <a href="./references#CD001808-bbs2-0044" title="Neri‐MejiaM , Pedraza‐AvilesAG . Active management of the third stage of labor: three schemes of oxytocin: randomised clinical trial. Ginecologia y Obstetricia De Mexico2016;84(5):306‐13. ">Neri‐Mejia 2016</a>; <a href="./references#CD001808-bbs2-0047" title="NuamsiriT , KaewkiattikunK . Prevention of postpartum hemorrhage with oxytocin versus ergometrine plus oxytocin in the third stage of labor. Thai Journal of Obstetrics and Gynaecology2016;24:97‐103. NuamsiriT , TCTR20150820001 . Prevention of postpartum hemorrhage with oxytocin versus ergometrine plus oxytocin in the third stage of labor. http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=1508. (20 May 2015) 2015. [TCTR20150820001] ">Nuamsiri 2016</a>; <a href="./references#CD001808-bbs2-0048" title="Oguz OrhanE , DilbazB , AksakalSE , AltinbasS , ErkayaS . Prospective randomized trial of oxytocin administration for active management of the third stage of labor. International Journal of Gynecology and Obstetrics2014;127(2):175‐9. ">Oguz Orhan 2014</a>; <a href="./references#CD001808-bbs2-0051" title="QuibelT , GhoutI , GoffinetF , SalomonLJ , FortJ , JavoiseS , et al. Active management of the third stage of labor with a combination of oxytocin and misoprostol to prevent postpartum hemorrhage: a randomized controlled trial. Obstetrics and Gynecology2016;128(4):805‐11. ">Quibel 2016</a>; <a href="./references#CD001808-bbs2-0065" title="Sunil KumarKS , ShyamS , BatakurkiP . Carboprost versus oxytocin for active management of third stage of labor: a prospective randomized control study. Journal of Obstetrics and Gynaecology of India2016;66(Suppl 1):S229‐34. ">Sunil 2016</a>). <a href="./references#CD001808-bbs2-0057" title="SharmaM , KaurP , KaurK , KaurA , KaurPK , KaurMM . A comparative study of oxytocin/misoprostol/methylergometrine for active management of the third stage of labor. Journal of Obstetrics and Gynecology of India2014;64(3):175‐9. ">Sharma 2014</a> was not a randomised trial. In addition, two studies that were included in the previous version of this review were excluded in this version as we felt that they could not be classified as either randomised or quasi‐randomised studies (<a href="./references#CD001808-bbs2-0025" title="BarbaroCA , SmithGO . Clinical trial of SE505 ‐ a new oxytocic mixture. Australian and New Zealand Journal of Obstetrics and Gynaecology1961;1:147‐50. ">Barbaro 1961</a>; <a href="./references#CD001808-bbs2-0058" title="SoivaK , KoistinenO . Clinical experience with simultaneous intramuscular injection of oxytocin and methylergometrine. Annales Chirurgiae et Gynaecologiae1964;53:173‐86. ">Soiva 1964</a>). One trial included a large group of women who were not randomised (data were collected retrospectively) and whose outcome data were inseparable from those that were randomised (<a href="./references#CD001808-bbs2-0058" title="SoivaK , KoistinenO . Clinical experience with simultaneous intramuscular injection of oxytocin and methylergometrine. Annales Chirurgiae et Gynaecologiae1964;53:173‐86. ">Soiva 1964</a>). </p> </section> </section> <section id="CD001808-sec-0095"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD001808-fig-0002">Figure 2</a>; <a href="#CD001808-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001808-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001808-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001808-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001808-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001808-sec-0096"> <h4 class="title">Allocation</h4> <p>Random sequence generation and allocation concealment were felt to be adequate and at low risk of bias in six of the 24 included studies (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>). In one study, we were unable to characterise risk of bias for sequence generation due to lack of description, although allocation concealment methods were adequate (<a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>). In another study, random sequence generation was adequate but there was insufficient detail regarding allocation concealment to make a judgement (<a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>). We assessed that six of the studies were at high risk of bias in both sequence generation and allocation concealment domains (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>). All of these studies were assessed to be quasi‐randomised due to the use of randomisation techniques that may have allowed for prediction or anticipation of study group assignment. Similarly, allocation treatment was either not concealed or performed in such a way (alternation or rotation) that could allow for possible identification. Another study was deemed to be at high risk of bias due to quasi‐randomisation, with insufficient information to assess allocation concealment (<a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>). There was not enough information to assess sequence generation or allocation concealment for nine studies (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0010" title="FugoNW , DieckmannWJ . A comparison of oxytocic drugs in the management of the placental stage. American Journal of Obstetrics and Gynecology1958;76:141‐6. ">Fugo 1958</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). </p> </section> <section id="CD001808-sec-0097"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel was assessed to be at high risk of bias in the majority of the included studies (16 of the 23 studies). Trials did not explicitly state a lack of blinding however due to the described methods it was presumed that blinding would not have been possible (different dosages or routes of administration without use of placebos) (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0011" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29:177‐80. ">Ilancheran 1990</a>; <a href="./references#CD001808-bbs2-0012" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal &amp; Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0021" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>; <a href="./references#CD001808-bbs2-0024" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81:596‐9. ">Vaughan Williams 1974</a>). Only six trials were deemed to be at low risk of bias in this domain (<a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0010" title="FugoNW , DieckmannWJ . A comparison of oxytocic drugs in the management of the placental stage. American Journal of Obstetrics and Gynecology1958;76:141‐6. ">Fugo 1958</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>), with the remaining trials having inadequate description to assess risk of bias.<br/> <br/> Blinding of outcome assessment was adequate in five studies as blinding of outcome assessors was explicitly described (<a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0009" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture. Australian &amp; New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965</a>; <a href="./references#CD001808-bbs2-0010" title="FugoNW , DieckmannWJ . A comparison of oxytocic drugs in the management of the placental stage. American Journal of Obstetrics and Gynecology1958;76:141‐6. ">Fugo 1958</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>). Five studies were judged to be at high risk of bias in this domain due to lack of blinding (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD001808-bbs2-0005" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD001808-bbs2-0007" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>; <a href="./references#CD001808-bbs2-0023" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52:694‐7. ">Sorbe 1978</a>). There was not adequate detail to assess the remaining studies with regards to detection bias. </p> </section> <section id="CD001808-sec-0098"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed that all participants who were randomised in the studies were accounted for in outcome data and analysis in 13 trials (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0004" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. Brtish Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0010" title="FugoNW , DieckmannWJ . A comparison of oxytocic drugs in the management of the placental stage. American Journal of Obstetrics and Gynecology1958;76:141‐6. ">Fugo 1958</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0014" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD001808-bbs2-0016" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0018" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>). Three trials were judged to be at high risk of attrition bias. One study excluded an unknown number of women after randomisation, however the authors did not clarify how many were lost from each group and how this attrition was addressed in the methods (<a href="./references#CD001808-bbs2-0002" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>). In another study there were 20 patients excluded after randomisation (of 180 enrolled) for various reasons, including need for surgical intervention (forceps or vacuum), unusually high levels of blood loss of unknown origin and placenta delivery times longer than 30 minutes after deliver (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>). We felt that excluding patients for high blood loss or evidence of retained placenta would place this study at high risk of bias given the nature of the clinical question being addressed. In a third study, the authors did not explicitly state how many patients were included in the analysis (<a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>). They reported that women with perineal and cervical lacerations were excluded from the study, however according to their results the majority of their patients received an episiotomy, which would have resulted in exclusion of significant numbers of patients after randomisation. </p> </section> <section id="CD001808-sec-0099"> <h4 class="title">Selective reporting</h4> <p>Two studies were felt to be at low risk of reporting bias (<a href="./references#CD001808-bbs2-0003" title="BaderW , AstS , HatzmannW . The significance of acupuncture in the third stage of labour. Deutsche Zeitschrift fur Akupunktur2000;43:264‐8. BaderW , AstS , ReinehrJ , HackmannJ , HatzmannW . Oxytocin versus Akupunktur in der Plazentarperiode ‐ eine prospektiv randomisierte Studie [abstract]. Geburtshilfe und Frauenheilkunde2000;60 Suppl 1:S73. ">Bader 2000</a>; <a href="./references#CD001808-bbs2-0010" title="FugoNW , DieckmannWJ . A comparison of oxytocic drugs in the management of the placental stage. American Journal of Obstetrics and Gynecology1958;76:141‐6. ">Fugo 1958</a>). One study was deemed to be at high risk of selective reporting (<a href="./references#CD001808-bbs2-0015" title="ModiV , GoelJK , KashyapA , AryaSB , KarJ , GoelR . Active management of third stage of labor: A comparison of various uterotonic. Journal of South Asian Federation of Obstetrics and Gynaecology ‐ SAFOG2014;6(3):151‐5. ">Modi 2014</a>), as some adverse outcomes of interest were reported incompletely. The authors report “side effects of various uterotonics” as outcomes, however data regarding vomiting, nausea, shivering, fever, headache and hypertension were incompletely reported for the oxytocin and methylergometrine groups. One other study was also judged to be at high risk for reporting bias (<a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>). The authors reported “adverse effects of the drugs” as secondary outcomes, and in the methods describe collection of data regarding postpartum haemoglobin level, however the data are not fully presented. They also report that “the methylergometrine group had the highest incidence of nausea and vomiting” but did not report this data completely. The remaining studies did not have enough detail provided to assess this domain. </p> </section> <section id="CD001808-sec-0100"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were identified in any of the included trials.</p> </section> </section> <section id="CD001808-sec-0101"> <h3 class="title" id="CD001808-sec-0101">Effects of interventions</h3> <p>See: <a href="./full#CD001808-tbl-0001"><b>Summary of findings for the main comparison</b> Oxytocin compared to no uterotonics or placebo for the third stage of labour to prevent postpartum haemorrhage</a>; <a href="./full#CD001808-tbl-0002"><b>Summary of findings 2</b> Oxytocin compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</a>; <a href="./full#CD001808-tbl-0003"><b>Summary of findings 3</b> Oxytocin + ergometrine compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</a> </p> <p>See: <a href="./full#CD001808-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD001808-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001808-tbl-0003">summary of findings Table 3</a>. </p> <p>Thes results are based on 23 studies with a total of 10,018 women.</p> <section id="CD001808-sec-0102"> <h4 class="title">1) Oxytocin versus no uterotonics or placebo</h4> <section id="CD001808-sec-0103"> <h5 class="title">Primary outcomes</h5> <section id="CD001808-sec-0104"> <h6 class="title">Blood loss greater than 500 mL</h6> <p>Prophylactic oxytocin compared with no uterotonics or placebo may reduce the risk of blood loss of 500 mL or more after delivery (average risk ratio (RR) 0.51, 95% confidence interval (CI) 0.37 to 0.72; 4162 women; 6 studies; Tau² = 0.10, I² = 75%; quality of evidence: low), <a href="./references#CD001808-fig-0006" title="">Analysis 1.1</a>. There were no subgroup differences observed between active and expectant management (<a href="./references#CD001808-fig-0015" title="">Analysis 2.1</a>), intravenous or intramuscular oxytocin (<a href="./references#CD001808-fig-0016" title="">Analysis 2.2</a>) or different doses of oxytocin (<a href="./references#CD001808-fig-0017" title="">Analysis 2.3</a>) for this outcome. </p> </section> <section id="CD001808-sec-0105"> <h6 class="title">Need for additional uterotonics</h6> <p>Prophylactic oxytocin probably reduces the need for additional uterotonics (average RR 0.54, 95% CI 0.36 to 0.80; 3135 women; 4 studies; Tau² =0.07, I² = 44%; quality of evidence: moderate), <a href="./references#CD001808-fig-0007" title="">Analysis 1.2</a>.There were no subgroup differences observed between active and expectant management (<a href="./references#CD001808-fig-0018" title="">Analysis 2.4</a>), intravenous or intramuscular oxytocin (<a href="./references#CD001808-fig-0019" title="">Analysis 2.5</a>) or different doses of oxytocin (<a href="./references#CD001808-fig-0020" title="">Analysis 2.6</a>) for this outcome. </p> </section> </section> <section id="CD001808-sec-0106"> <h5 class="title">Secondary outcomes</h5> <p>Prophylactic oxytocin compared with no uterotonics or placebo may reduce the risk of blood loss 1000 mL or more after delivery (RR 0.59, 95% CI 0.42 to 0.83; 4123 women; 5 studies; quality of evidence: low),<a href="./references#CD001808-fig-0008" title="">Analysis 1.3</a>. There may be no difference in the risk of needing a blood transfusion in women receiving oxytocin compared to no uterotonics or placebo (RR 0.88, 95% CI 0.44 to 1.78; 3081 women; 3 studies; quality of evidence: low), <a href="./references#CD001808-fig-0009" title="">Analysis 1.4</a>, and there is probably no difference in the risk of developing a postpartum haemoglobin (Hb) &lt; 7 g/dL (RR 0.64, 95% CI 0.18 to 2.26; 1073 women; 2 studies; quality of evidence: moderate), <a href="./references#CD001808-fig-0012" title="">Analysis 1.7</a>. It is unclear if oxytocin is associated with a reduction in mean blood loss (mean blood loss in mL: ‐99.13, 95% CI ‐181.40 to ‐16.85; 1359 women; 5 studies; quality of evidence: very low), <a href="./references#CD001808-fig-0011" title="">Analysis 1.6</a>. </p> <p>Oxytocin may be associated with an increased risk of a third stage greater than 30 minutes (RR 2.55, 95% CI 0.88 to 7.44; 1947 women; 1 study; quality of evidence: moderate), <a href="./references#CD001808-fig-0010" title="">Analysis 1.5</a>. However the CI is wide and crosses 1.0, which indicates that there may be little or no difference between oxytocin and no uterotonic or placebo. This result is based on a single study of 1947 women, where 20 of 1289 women in the oxytocin group experienced this outcome versus four of 658 women in the no uterotonics group. It is uncertain whether oxytocin affects the mean length of the third stage of labour (mean length of the third stage of labour in minutes: ‐3.61, 95% CI ‐9.06 to 1.83; 294 women; 3 studies; quality of evidence: very low), <a href="./references#CD001808-fig-0013" title="">Analysis 1.8</a>, or the risk of needing manual removal of the placenta (RR 1.27, 95% CI 0.89 to 1.82; 4281 women; 6 studies; quality of evidence: very low), <a href="./references#CD001808-fig-0014" title="">Analysis 1.9</a>, given the very low certainty of this evidence. </p> </section> <section id="CD001808-sec-0107"> <h5 class="title">Outcomes not reported</h5> <p>The following pre‐specified outcomes were not reported for this comparison as none of the included trials reported these outcomes: maternal all‐cause mortality, diastolic blood pressure &gt; 100 mg Hg between delivery of the baby and discharge from the labour ward, vomiting between delivery of the baby and discharge from the labour ward, headache between delivery of the baby and discharge from the labour ward, shock, transfer to a higher level of care, mortality from causes other than bleeding, maternal satisfaction with therapy, quality of life, breastfeeding. </p> </section> </section> <section id="CD001808-sec-0108"> <h4 class="title">2) Oxytocin versus ergot alkaloids</h4> <section id="CD001808-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD001808-sec-0110"> <h6 class="title">Blood loss greater than 500 mL</h6> <p>It is uncertain whether oxytocin reduces the likelihood of blood loss 500 mL or more after delivery (average RR 0.84, 95% CI 0.56 to 1.25; 3082 women; 10 studies; Tau² = 0.14, I² = 49%; quality of evidence: very low)<i>,</i><a href="./references#CD001808-fig-0021" title="">Analysis 3.1</a>, compared to ergot alkaloids, because the certainty of this evidence is very low. There were no subgroup differences observed between active and expectant management (<a href="./references#CD001808-fig-0032" title="">Analysis 4.1</a>), intravenous or intramuscular oxytocin (<a href="./references#CD001808-fig-0033" title="">Analysis 4.2</a>) or different doses of oxytocin (<a href="./references#CD001808-fig-0034" title="">Analysis 4.3</a>) for this outcome. </p> </section> <section id="CD001808-sec-0111"> <h6 class="title">Need for additional uterotonics</h6> <p>It is also unclear whether oxytocin reduces the need for additional uterotonics compared to ergot alkaloids (average RR 0.89, 95% CI 0.43 to 1.81; 2178 women; 8 studies; Tau² = 0.76, I² = 79%; quality of evidence: very low), <a href="./references#CD001808-fig-0022" title="">Analysis 3.2</a>, due to the very low certainty of this evidence. There were no differences observed in any of the prespecified subgroups (<a href="./references#CD001808-fig-0035" title="">Analysis 4.4</a>; <a href="./references#CD001808-fig-0036" title="">Analysis 4.5</a>; <a href="./references#CD001808-fig-0037" title="">Analysis 4.6</a>). </p> </section> </section> <section id="CD001808-sec-0112"> <h5 class="title">Secondary outcomes</h5> <p>Similarly, the quality of evidence was very low for the outcomes of blood loss of 1000 mL or more after delivery (RR 1.13, 95% CI 0.63 to 2.01; 1577 women; 3 studies; quality of evidence: very low), <a href="./references#CD001808-fig-0023" title="">Analysis 3.3</a>, need for blood transfusion (average RR 1.37, 95% CI 0.34 to 5.51; 1578 women; 7 studies; Tau² = 1.34, I² = 45%; quality of evidence: very low), <a href="./references#CD001808-fig-0024" title="">Analysis 3.4</a>, as well as mean blood loss (mean blood loss in mL: ‐13.97, 95% CI ‐43.70 to 15.76; 3598 women; 11 studies; quality of evidence: very low), <a href="./references#CD001808-fig-0027" title="">Analysis 3.7</a>, making any benefit of oxytocin over ergot alkaloids uncertain. </p> <p>Oxytocin probably increases the risk of a third stage greater than 30 minutes compared to ergot alkaloids (RR 4.69, 95% CI 1.63 to 13.45; 450 women; 2 studies; quality of evidence: moderate), <a href="./references#CD001808-fig-0025" title="">Analysis 3.5</a>, although it is uncertain whether or not this translates into an increased risk of manual placental removal (average RR 1.10, 95% CI 0.39 to 3.10; 3127 women; 8 studies; Tau² = 1.07, I² = 76%; quality of evidence: very low), <a href="./references#CD001808-fig-0029" title="">Analysis 3.9</a>. It is unclear whether or not oxytocin affects the mean length of the third stage of labour (mean length of the third stage in minutes: 0.09, 95% CI ‐0.44 to 0.61; 2892 women; 8 studies; quality of evidence: very low), <a href="./references#CD001808-fig-0028" title="">Analysis 3.8</a>. </p> <p>Oxytocin may be associated with a lower risk of diastolic blood pressure &gt; 100 mm Hg after delivery (average RR 0.28, 95% CI 0.04 to 2.05; 960 women; 3 studies; Tau² = 1.23, I² = 50%; quality of evidence: low), <a href="./references#CD001808-fig-0026" title="">Analysis 3.6</a>, although the 95% CI is very wide and indicates that there may possibly be little or no risk reduction. Oxytocin is probably associated with a lower risk of vomiting than ergot alkaloids (RR 0.09, 95% CI 0.05 to 0.14; 1991 women; 7 studies; quality of evidence: moderate), <a href="./references#CD001808-fig-0030" title="">Analysis 3.10</a>. The impact of oxytocin on headaches is uncertain (average RR 0.19, 95% CI 0.03 to 1.02; 1543 women; 5 studies; Tau² = 2.54, I² = 72%; quality of evidence: very low), <a href="./references#CD001808-fig-0031" title="">Analysis 3.11</a>. </p> </section> <section id="CD001808-sec-0113"> <h5 class="title">Outcomes not reported</h5> <p>The following pre‐specified outcomes were not reported for this comparison as none of the included trials reported these outcomes: maternal all‐cause mortality, maternal Hb concentration &lt; 7 g/dL 24 to 48 hours postpartum, shock, transfer to a higher level of care, mortality from causes other than bleeding, maternal satisfaction with therapy, quality of life, breastfeeding. </p> </section> </section> <section id="CD001808-sec-0114"> <h4 class="title">3) Oxytocin‐ergometrine versus ergot alkaloids</h4> <section id="CD001808-sec-0115"> <h5 class="title">Primary outcomes</h5> <section id="CD001808-sec-0116"> <h6 class="title">Blood loss greater than 500 mL</h6> <p>Oxytocin‐ergometrine may slightly reduce the risk of blood loss greater than 500 mL or more after delivery compared to ergot alkaloids (RR 0.44, 95% CI 0.20 to 0.94; 1168 women; 3 studies; quality of evidence: low), <a href="./references#CD001808-fig-0038" title="">Analysis 5.1</a>. This outcome is based on data from only quasi‐randomised trials deemed to be at high risk of bias. </p> </section> <section id="CD001808-sec-0117"> <h6 class="title">Maternal all‐cause mortality</h6> <p>One study reported maternal all‐cause mortality as an outcome, however no events in either the oxytocin‐ergometrine group (391 women) or the ergot alkaloid group (416 women) were reported, so an effect could not be estimated. </p> </section> </section> <section id="CD001808-sec-0118"> <h5 class="title">Secondary outcomes</h5> <p>The effect of oxytocin‐ergometrine compared to ergot alkaloids on mean blood loss is uncertain (mean blood loss in mL: 61.00, 95% CI ‐0.90 to 122.90; 27 women; 1 study; quality of evidence: very low), <a href="./references#CD001808-fig-0040" title="">Analysis 5.3</a>, and there may be no difference in the risk of manual removal of the placenta (RR 1.06, 95% CI 0.31 to 3.65; 807 women; 1 study; quality of evidence: low), <a href="./references#CD001808-fig-0039" title="">Analysis 5.2</a>. </p> <p>The need for additional uterotonics, blood loss greater than 1000 mL or more after delivery, blood transfusion, third stage greater than 30 minutes and diastolic hypertension were not outcomes reported in the included studies. </p> </section> <section id="CD001808-sec-0119"> <h5 class="title">Outcomes not reported</h5> <p>The following pre‐specified outcomes were not reported for this comparison as none of the included trials reported these outcomes: need for additional uterotonics, blood loss 1000 mL or more after delivery, blood transfusion, third stage greater than 30 minutes, diastolic blood pressure &gt; 100 mg Hg between delivery of the baby and discharge from the labour ward, maternal Hb concentration &lt; 7 g/dL 24 to 48 hours postpartum, vomiting between delivery of the baby and discharge from the labour ward, headaches between delivery of the baby and discharge from the labour ward, shock, transfer to a higher level of care, mortality from causes other than bleeding, maternal satisfaction with therapy, quality of life, breastfeeding. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001808-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001808-sec-0120"></div> <section id="CD001808-sec-0121"> <h3 class="title" id="CD001808-sec-0121">Summary of main results</h3> <p>Compared to no uterotonics or placebo, oxytocin may reduce the risk of blood loss greater than 500 mL and greater than 1000 mL (low‐quality evidence<i>),</i> and probably reduces the need for additional uterotonics (moderate‐quality evidence)<i>.</i> Oxytocin probably does not affect the risk of developing severe anaemia (haemoglobin (Hb) &lt; 7 g/dL) (moderate‐quality evidence), and may not affect the risk of needing a blood transfusion (low‐quality evidence). The use of oxytocin may be associated with an increased risk of a third stage of labour greater than 30 minutes (moderate‐quality evidence<i>)</i>, although whether that translates into greater risk of needing a manual placental removal is uncertain (very low‐quality evidence). </p> <p>It is unclear whether oxytocin affects the risk of excessive blood loss after delivery compared to ergot alkaloids, as the quality of evidence for outcomes related to blood loss (blood loss greater than 500 mL, blood loss greater than 1000 mL, need for additional uterotonics, need for blood transfusion, mean blood loss) was very low. Oxytocin probably increases the risk of a third stage of labour greater than 30 minutes <i>(</i> moderate‐quality evidence), however it is uncertain whether or not this translates into an increased risk of manual placental removal or a difference in the mean length of the third stage of labour (very low‐quality evidence). This must be weighed against potential side effects, as ergot alkaloids are probably associated with a higher risk of vomiting (moderate‐quality evidence), and may be associated with a higher risk of diastolic hypertension (low‐quality evidence)<i>.</i> </p> <p>The combination of oxytocin and ergometrine compared to ergot alkaloids alone may be associated with a slight reduction in the risk of blood loss greater than 500 mL, based on low‐quality evidence from only quasi‐randomised trials at high risk of bias. The effect on mean blood loss is uncertain (very low‐quality evidence)<i>,</i> and there may be no difference in the risk of manual placental removal (low‐quality evidence). </p> </section> <section id="CD001808-sec-0122"> <h3 class="title" id="CD001808-sec-0122">Overall completeness and applicability of evidence</h3> <section id="CD001808-sec-0123"> <h4 class="title">Population</h4> <p>The patient population in the majority of the studies were women in relatively good health, as many studies excluded women with medical co‐morbidities (diabetes, hypertensive disease, renal disease, pre‐existing anaemia). Although many women with risk factors associated with an increased risk of postpartum haemorrhage (PPH) were also excluded (prior PPH, grand multiparity, multiple gestations), generalising these data to those specific patient groups seems reasonable as similar etiologies for PPH are likely to exist in a lower‐risk population. Gestational age criteria were explicitly stated in a minority of the included studies, ranging from inclusion of full‐term patients only and inclusion of patients at 28 weeks' gestation or greater. Women who delivered by caesarean section were not included in the analysis, and many studies also excluded women with an operative vaginal delivery. </p> </section> <section id="CD001808-sec-0124"> <h4 class="title">Intervention</h4> <p>Oxytocin was given by intramuscular (IM) and intravenous (IV) route at doses ranging from 5 international units (IU) to 10 IU in the included trials, with most trials lacking clarification of whether IV route was administered by bolus or infusion. While this is reflective of practice in some centres, many also choose to use higher doses administered by IV infusion for variable periods of time following delivery. When comparing oxytocin to no uterotonics, active management or some component of active management of the third stage of labour (AMTSL) was applied to the comparator group in approximately half of the studies, but none of the studies applied active management to the oxytocin treatment groups. </p> </section> <section id="CD001808-sec-0125"> <h4 class="title">Comparators</h4> <p>In this review oxytocin was compared to either no uterotonics or placebo or ergot alkaloids (alone or in combination with ergometrine). As current recommendations from the World Health Organization and multiple obstetric professional organisations recommend the use of active management of the third stage including the use of a uterotonic, most recent studies evaluate the use of oxytocin compared to another uterotonic agent instead of placebo. Ergot alkaloids (methylergometrine or ergometrine) were given in the majority of studies by either IV or IM route and doses ranging from 0.2 mg to 0.5 mg, which reflects typical practice in most centres. Oxytocin‐ergometrine (Syntometrine) was given at the standard dose in the included trials; currently this medication is currently unavailable in the USA. Also of note, approximately half of the studies comparing oxytocin with ergometrine applied active management to all treatment groups, while most of the remaining studies did not explicitly state their practice regarding active management. </p> </section> <section id="CD001808-sec-0126"> <h4 class="title">Outcomes</h4> <p>Most studies included direct blood loss evaluation with some form of gravimetric measurement described. While most studies did not explicitly describe over what period of time the blood loss was measured, the few that did mention this described measurement of blood loss accumulated within one hour of delivery. Most studies reported blood loss greater than 500 mL, in line with the most commonly utilised definition of PPH, although a third of the studies did specifically report blood loss greater than 1000 mL. Outcomes related to retained placenta were examined in many trials, with most reporting data either for manual placental removal or a third stage greater than 30 minutes. None of the included studies included surrogate outcomes for significant maternal morbidity from haemorrhage such as transfer to higher level of care or shock, and only one reported maternal mortality as an outcome (although there were no events in either group). </p> </section> <section id="CD001808-sec-0127"> <h4 class="title">Setting</h4> <p>The evidence in this review is based upon trials from a wide range of low‐ to high‐income countries in hospital settings, although one trial included an undisclosed number of women who delivered at home attended by a midwife (<a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>). All studies included data from patients at tertiary medical hospitals, many of them teaching hospitals, although several also included patients recruited from community hospitals. </p> </section> <section id="CD001808-sec-0128"> <h4 class="title">Summary</h4> <p>Overall, the evidence in this review is directly applicable to healthy women at lower risk of PPH, delivering vaginally in hospital settings at greater than 28 weeks. Extending applicability of these findings with regards to impact on blood loss seems reasonable in women undergoing caesarean delivery, and those with certain risk factors (prior PPH, multiple gestations, grand multiparity). Women with coagulation disorders or other haematological issues (those on anticoagulation) may have different or additional mechanisms underlying postpartum bleeding, and should still receive the usual third stage management although additional therapies may be necessary in the event of PPH depending on the underling disorder. Application of the findings to women delivering outside of a hospital but with access to uterotonic medications is also reasonable given expected similarities in the underlying mechanisms of PPH. </p> <p>We had planned to assess multiple outcomes for each of our three comparisons, with the goal of evaluating effects of interventions that would reflect a wide range of potential maternal morbidity. In this updated version of the review, we incorporated several additional important outcomes that have been recommended as part of a core outcome set for reporting in PPH prevention studies (<a href="./references#CD001808-bbs2-0091" title="MeherS , CuthbertA , KirkhamJJ , WilliamsonP , AbalosE , AflaifelN , et al. Core outcome sets for prevention and treatment of postpartum hemorrhage: an international Delphi consensus study. British Journal of Obstetrics and Gynaecology2018;126(1):83‐93. [DOI: 10.1111/1471‐0528.15335] ">Meher 2018</a>). It is important to note that none of the included trials reported many of our pre‐specified outcomes, including maternal mortality (all‐cause and from causes other than bleeding), shock, transfer to a higher level of care, patient‐reported outcomes (maternal satisfaction with therapy and quality of life) and neonatal outcomes (breastfeeding). </p> <p>Most studies that compared oxytocin versus no uterotonics or with ergot alkaloids included multiple important outcomes and surrogate outcomes aimed at assessing blood loss. Data on complications of delayed placental delivery were more limited for trials comparing oxytocin with no uterotonics, with only one trial reporting outcomes for a third stage greater than 30 minutes (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>), although several trials did report on the incidence of manual placental removal (<a href="./references#CD001808-bbs2-0001" title="Abdel‐AleemH , SingataM , Abdel‐AleemM , MshweshweN , WilliamsX , HofmeyrGJ . Uterine massage to reduce postpartum hemorrhage after vaginal delivery. International Journal of Gynecology &amp; Obstetrics2010;111(1):32‐6. ">Abdel‐Aleem 2010</a>; <a href="./references#CD001808-bbs2-0006" title="DeGrootAN , VanRoosmalenJ , VanDongenPW , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75:464‐8. ">De Groot 1996</a>; <a href="./references#CD001808-bbs2-0013" title="JerbiM , HidarS , ElmoueddebS , ChaiebA , KhairiH . Oxytocin in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2007;96(3):198‐9. ">Jerbi 2007</a>; <a href="./references#CD001808-bbs2-0017" title="NordstromL , FogelstamK , FridmanG , LarssonA , RydhstroemH . Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology1997;104:781‐6. ">Nordstrom 1997</a>; <a href="./references#CD001808-bbs2-0019" title="PierreF , MesnardL , BodyG . For a systematic policy of iv oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1992;43:131‐5. ">Pierre 1992</a>; <a href="./references#CD001808-bbs2-0020" title="PoeschmannRP , DoesburgWH , EskesTK . A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1991;98:528‐30. ">Poeschmann 1991</a>). In contrast, most of the trials comparing oxytocin with ergot alkaloids reported third stage placental complications including mean length of the third stage and manual placental removal, although only two specifically reported the outcome of third stage greater than 30 minutes (<a href="./references#CD001808-bbs2-0008" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. ">Ezeama 2014</a>; <a href="./references#CD001808-bbs2-0022" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>). Potential adverse effects of oxytocin were not reported in trials comparing oxytocin with no uterotonics, possibly secondary to the relatively favourable side‐effect profile of oxytocin when given in smaller limited doses. As ergot alkaloids have been associated with multiple side effects due to vasoconstriction (<a href="./references#CD001808-bbs2-0081" title="DeGrootAN , VanDongenPW , VreeTB , HeksterYA , VanRoosmalenJ . Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynecology. Drugs1998;56(4):523‐35. ">De Groot 1998</a>; <a href="./references#CD001808-bbs2-0090" title="LiabsuetrakulT , ChoobunT , PeeyananjarassriK , IslamQM . Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database of Systematic Reviews2018, Issue 6. [DOI: 10.1002/14651858.CD005456.pub3] ">Liabsuetrakul 2018</a>), many studies reported outcomes for side effects including diastolic hypertension, vomiting and headaches. </p> <p>Overall, evidence on oxytocin‐ergometrine compared to ergot alkaloids was very limited, with only four trials identified that included this comparison (total of 1198 women). Data on a limited number of outcomes were reported, including blood loss greater than 500 mL, mean blood loss and manual removal of the placenta. </p> </section> </section> <section id="CD001808-sec-0129"> <h3 class="title" id="CD001808-sec-0129">Quality of the evidence</h3> <p>We graded the evidence for all outcomes using the GRADE approach, and reported the findings for the outcomes we deemed most important in our 'Summary of findings' tables (<a href="./full#CD001808-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD001808-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001808-tbl-0003">summary of findings Table 3</a>). See the 'Risk of Bias' summary (<a href="#CD001808-fig-0003">Figure 3</a>) for our detailed assessment of risk of bias for each of the included studies. </p> <p>Evidence for the comparison of oxytocin versus no uterotonics or placebo ranged from very low to moderate quality. For our primary outcomes, the evidence was deemed to be of low to moderate quality due to risk of bias due to lack of blinding, as well as substantial heterogeneity. For secondary outcomes including blood loss greater than 1000 mL and need for blood transfusion, the quality of evidence was downgraded to low due to lack of blinding and wide confidence intervals resulting in imprecision. The evidence for a third stage greater than 30 minutes was based on data from single study and assessed as moderate quality, due to concern over imprecision as confidence intervals were wide and there were very few events. Other evidence evaluating retained placenta (mean length of the third stage and need for manual placental removal) was of very low quality due to serious concerns regarding risk of bias in multiple domains, as well as both substantial heterogeneity and imprecision. </p> <p>Evidence for the comparison of oxytocin versus ergot alkaloids ranged from very low to moderate quality, with the majority of outcomes assessed as very low to low quality of evidence. Evidence for our primary outcomes of blood loss greater than 500 mL and need for additional uterotonics was downgraded to very low due to serious methodological limitations increasing the risk of bias, wide confidence intervals resulting in imprecision and substantial heterogeneity leading demonstrating inconsistency. Secondary outcomes of blood loss of 1000 mL or more and need for transfusion were also assessed as very low quality for the same reasons. The evidence for risk of third stage greater than 30 minutes was deemed of moderate quality due to lack of precision (there were wide confidence intervals, few events and one of the two studies had no reported events). Evidence for manual placental removal was of very low quality due to serious methodological limitations across multiple domains, wide confidence intervals and substantial heterogeneity. Evidence for various side effects was assessed as low quality for elevated diastolic blood pressure due to concerns regarding heterogeneity and wide confidence intervals, and as moderate quality for vomiting due to risk of bias concerns in reporting trials. Evidence for headaches was of very low quality due to serious methodological concerns, as well as serious imprecision and inconsistency amongst trials. We produced funnel plots for analyses that included 10 or more studies (<a href="./references#CD001808-fig-0021" title="">Analysis 3.1</a>, <a href="#CD001808-fig-0004">Figure 4</a>; <a href="./references#CD001808-fig-0027" title="">Analysis 3.7</a>, <a href="#CD001808-fig-0005">Figure 5</a>), and neither raised concern for publication bias. </p> <div class="figure" id="CD001808-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.1 Blood loss 500 mL or more after delivery." data-id="CD001808-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.1 Blood loss 500 mL or more after delivery. </p> </div> </div> </div> <div class="figure" id="CD001808-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.7 Mean blood loss (mL)." data-id="CD001808-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.7 Mean blood loss (mL). </p> </div> </div> </div> <p>Evidence for the comparison of oxytocin‐ergometrine versus ergot alkaloids was very limited, but ranged from very low to low quality. For all three outcomes with data reported, there were concerns regarding lack of blinding and randomisation methods increasing the risk of bias, as well as wide confidence intervals combined with few events concerning for imprecision. </p> </section> <section id="CD001808-sec-0130"> <h3 class="title" id="CD001808-sec-0130">Potential biases in the review process</h3> <p>We attempted to minimise the introduction of bias in this review by adhering to the Cochrane methods at all stages of data collection and analysis. Two review authors independently assessed trials for inclusion, extracted data and assessed risk of bias. Any discrepancies were resolved by discussion or by involvement of a third author. GRADE assessment for quality of evidence was assessed by two review authors. </p> </section> <section id="CD001808-sec-0131"> <h3 class="title" id="CD001808-sec-0131">Agreements and disagreements with other studies or reviews</h3> <p>This is the most comprehensive published systematic review specifically comparing oxytocin with no uterotonics or ergot alkaloids for the prevention of PPH. The findings are overall consistent with findings from other related studies that have included oxytocin as a comparison group. One review compared oxytocin with no intervention or standard care in the third stage of labour in out‐of‐hospital settings and found that oxytocin probably decreased the incidence of PPH greater than 500 mL, although evidence for all other outcomes was lacking or the interpretation was limited due to low quality of evidence (<a href="./references#CD001808-bbs2-0096" title="PantojaT , AbalosE , ChapmanE , VeraC , SerranoVP . Oxytocin for preventing postpartum haemorrhage (PPH) in non‐facility birth settings. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD011491.pub2] ">Pantoja 2016</a>). A recent network meta‐analysis was undertaken to investigate and rank various uterotonic regimens according to their effectiveness and side‐effect profiles (<a href="./references#CD001808-bbs2-0085" title="GallosID , PapadopoulouA , ManR , AthanasopoulosN , TobiasA , PriceMJ , et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 12. [DOI: 10.1002/14651858.CD011689.pub3] ">Gallos 2018</a>). They identified oxytocin‐ergometrine, oxytocin combined with misoprostol, and carbetocin, as being the most effective drugs for reducing postpartum blood loss compared to oxytocin. The regimens associated with the highest risk of side effects compared to oxytocin alone were oxytocin‐ergometrine (increased risk of nausea, vomiting,and diarrhoea), and oxytocin plus misoprostol (increased risk of nausea, vomiting, shivering, fever, and diarrhoea). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001808-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD001808-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001808-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001808-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.1 Blood loss 500 mL or more after delivery." data-id="CD001808-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.1 Blood loss 500 mL or more after delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.7 Mean blood loss (mL)." data-id="CD001808-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Oxytocin versus ergot alkaloids, outcome: 3.7 Mean blood loss (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 1 Blood loss 500 mL or more after delivery." data-id="CD001808-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 1 Blood loss 500 mL or more after delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 2 Need for additional uterotonics." data-id="CD001808-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 2 Need for additional uterotonics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 3 Blood loss 1000 mL or more after delivery." data-id="CD001808-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 3 Blood loss 1000 mL or more after delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 4 Blood transfusion." data-id="CD001808-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 4 Blood transfusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 5 Third stage greater than 30 minutes." data-id="CD001808-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 5 Third stage greater than 30 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 6 Mean blood loss (mL)." data-id="CD001808-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 6 Mean blood loss (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 7 Maternal haemoglobin concentration (Hb) &lt; 7 g/dL 24‐48 hours PP." data-id="CD001808-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 7 Maternal haemoglobin concentration (Hb) &lt; 7 g/dL 24‐48 hours PP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 8 Mean length of third stage (minutes)." data-id="CD001808-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 8 Mean length of third stage (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 9 Manual removal of the placenta." data-id="CD001808-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Oxytocin versus no uterotonics or placebo, Outcome 9 Manual removal of the placenta. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 1 Blood loss 500 mL or more after delivery; active v. expectant management." data-id="CD001808-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 1 Blood loss 500 mL or more after delivery; active v. expectant management. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin." data-id="CD001808-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU." data-id="CD001808-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 4 Need for additional uterotonics; active v. expectant management." data-id="CD001808-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 4 Need for additional uterotonics; active v. expectant management. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 5 Need for additional uterotonics; IM v. IV oxytocin." data-id="CD001808-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 5 Need for additional uterotonics; IM v. IV oxytocin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU." data-id="CD001808-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Oxytocin versus no uterotonics or placebo‐subgroup analyses, Outcome 6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 1 Blood loss 500 mL or more after delivery." data-id="CD001808-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 1 Blood loss 500 mL or more after delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 2 Need for additional uterotonics." data-id="CD001808-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 2 Need for additional uterotonics.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 3 Blood loss 1000 mL or more after delivery." data-id="CD001808-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 3 Blood loss 1000 mL or more after delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 4 Blood transfusion." data-id="CD001808-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 4 Blood transfusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 5 Third stage &gt; 30 minutes." data-id="CD001808-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 5 Third stage &gt; 30 minutes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 6 Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward." data-id="CD001808-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 6 Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 7 Mean blood loss (mL)." data-id="CD001808-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 7 Mean blood loss (mL).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 8 Mean length of third stage (minutes)." data-id="CD001808-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 8 Mean length of third stage (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 9 Manual removal of the placenta." data-id="CD001808-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 9 Manual removal of the placenta.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 10 Vomiting between delivery of the baby and discharge from the labour ward." data-id="CD001808-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 10 Vomiting between delivery of the baby and discharge from the labour ward. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxytocin versus ergot alkaloids, Outcome 11 Headaches between delivery of the baby and discharge from the labour ward." data-id="CD001808-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Oxytocin versus ergot alkaloids, Outcome 11 Headaches between delivery of the baby and discharge from the labour ward. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 1 Blood loss 500 mL or more after delivery; active v. expectant management." data-id="CD001808-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 1 Blood loss 500 mL or more after delivery; active v. expectant management. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin." data-id="CD001808-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU." data-id="CD001808-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 4 Need for additional uterotonics; active v. expectant management." data-id="CD001808-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 4 Need for additional uterotonics; active v. expectant management. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 5 Need for additional uterotonics; IM v. IV oxytocin." data-id="CD001808-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 5 Need for additional uterotonics; IM v. IV oxytocin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU." data-id="CD001808-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Oxytocin versus ergot alkaloids‐‐subgroup analyses, Outcome 6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 1 Blood loss 500 mL or more after delivery." data-id="CD001808-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 1 Blood loss 500 mL or more after delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 2 Manual removal of the placenta." data-id="CD001808-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 2 Manual removal of the placenta. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 3 Mean blood loss (mL)." data-id="CD001808-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 3 Mean blood loss (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 4 Maternal all‐cause mortality." data-id="CD001808-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Oxytocin + ergometrine versus ergot alkaloids, Outcome 4 Maternal all‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Oxytocin + ergometrine versus ergot alkaloids‐‐subgroup analyses, Outcome 1 Blood loss 500 mL or more after delivery; active v. expectant management." data-id="CD001808-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Oxytocin + ergometrine versus ergot alkaloids‐‐subgroup analyses, Outcome 1 Blood loss 500 mL or more after delivery; active v. expectant management. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Oxytocin + ergometrine versus ergot alkaloids‐‐subgroup analyses, Outcome 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin." data-id="CD001808-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Oxytocin + ergometrine versus ergot alkaloids‐‐subgroup analyses, Outcome 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 1 Blood loss 500 mL or more after delivery; active v. expectant management." data-id="CD001808-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 1 Blood loss 500 mL or more after delivery; active v. expectant management. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin." data-id="CD001808-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU." data-id="CD001808-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 4 Need for additional uterotonics; active v. expectant management." data-id="CD001808-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 4 Need for additional uterotonics; active v. expectant management. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 5 Need for additional uterotonics; IM v. IV oxytocin." data-id="CD001808-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 5 Need for additional uterotonics; IM v. IV oxytocin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001808-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/urn:x-wiley:14651858:media:CD001808:CD001808-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_t/tCD001808-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU." data-id="CD001808-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Oxytocin versus no uterotonics or placebo‐‐subgroup analyses, Outcome 6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/media/CDSR/CD001808/image_n/nCD001808-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001808-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxytocin compared to no uterotonics or placebo for the third stage of labour to prevent postpartum haemorrhage</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oxytocin compared to no uterotonics or placebo for the third stage of labour to prevent postpartum haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Setting:</b> hospital labour wards and home births in France, Germany, the Netherlands, Sweden, South Africa, Tunisia, and the UK<br/> <b>Intervention:</b> oxytocin<br/> <b>Comparison:</b> no uterotonics or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no uterotonics</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oxytocin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 500 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/> (0.37 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4162<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000<br/> (89 to 172) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Need for additional uterotonics</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/> (0.36 to 0.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3135<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (41 to 91) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maternal all‐cause mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 1000 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/> (0.42 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4123<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (20 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/> (0.44 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3081<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (5 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Third stage greater than 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.55<br/> (0.88 to 7.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1947<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (5 to 45) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Lack of blinding in the majority of trials raises concern for biased outcome assessment as most trials utilised visual estimation of blood loss (risk of bias ‐1) </p> <p><sup>2</sup> Large variations in effect and non‐overlapping 95% confidence intervals; I<sup>2</sup> = 75% indicating substantial heterogeneity (inconsistency ‐1) </p> <p><sup>3</sup> Lack of participant blinding in some trials may bias decisions to administer additional uterotonics (risk of bias ‐1) </p> <p><sup>4</sup> Few events and wide 95% confidence intervals (imprecision ‐1) </p> <p><sup>5</sup> Lack of personnel blinding may bias decisions to administer blood transfusions (risk of bias ‐1) </p> <p><sup>6</sup> Wide 95% confidence intervals including line of no effect (imprecision ‐1) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxytocin compared to no uterotonics or placebo for the third stage of labour to prevent postpartum haemorrhage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001808-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oxytocin compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oxytocin compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Setting:</b> hospital labour wards and home births in the Netherlands, Sweden, South Africa, Japan, Singapore, India, Nepal, Tunisia, Nigeria, New Zealand, the UK and the USA<br/> <b>Intervention:</b> oxytocin<br/> <b>Comparison:</b> ergot alkaloids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ergot alkaloids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oxytocin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 500 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.56 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3082<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>116 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/> (65 to 145) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Need for additional uterotonics</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.43 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2178<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000<br/> (40 to 170) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal all‐cause mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 1000 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.63 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1577<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/> (20 to 64) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/> (0.34 to 5.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1578<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>3 5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (4 to 71) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Third stage &gt; 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.69<br/> (1.63 to 13.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>450<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000<br/> (29 to 240) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.28<br/> (0.04 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>960<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (2 to 90) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Studies with serious methodological limitations in multiple domains (risk of bias ‐2) </p> <p><sup>2</sup> Wide 95% confidence intervals including line of no effect (imprecision ‐1) </p> <p><sup>3</sup> Studies with serious methodological limitations (risk of bias ‐1) </p> <p><sup>4</sup> Large variations in effect and non‐overlapping 95% confidence intervals; I<sup>2</sup> = 79% indicating substantial heterogeneity (inconsistency ‐1) </p> <p><sup>5</sup> Large variations in effect; I<sup>2</sup> = 45% indicating substantial heterogeneity (inconsistency ‐1) </p> <p><sup>6</sup> Wide 95% confidence intervals including line of no effect, and few events (imprecision ‐1) </p> <p><sup>7</sup> Wide 95% confidence interval and few events, including one study with no events (imprecision ‐1) </p> <p><sup>8</sup> Unclear allocation concealment in majority of studies (risk of bias ‐1) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oxytocin compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001808-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oxytocin + ergometrine compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oxytocin + ergometrine compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Setting:</b> hospital labour wards in Sweden, Singapore, Tunisia, and the UK<br/> <b>Intervention:</b> oxytocin + ergometrine<br/> <b>Comparison:</b> ergot alkaloids </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ergot alkaloids</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oxytocin + ergometrine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 500 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44<br/> (0.20 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1168<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (7 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Need for additional uterotonics</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Maternal all‐cause mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>807<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It was not possible to obtain effect estimates as there were no events reported.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood loss 1000 mL or more after delivery</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood transfusion</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Third stage &gt; 30 minutes</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This outcome was not reported in any of the included studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Lack of blinding of estimated outcome assessment, and concern regarding randomisation methods (risk of bias ‐1) </p> <p><sup>2</sup> Few events and wide 95% confidence intervals (imprecision ‐1) </p> <p><sup>3</sup> No events reported for this outcome (imprecision ‐1) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oxytocin + ergometrine compared to ergot alkaloids for the third stage of labour to prevent postpartum haemorrhage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/full#CD001808-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001808-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oxytocin versus no uterotonics or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood loss 500 mL or more after delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.37, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Need for additional uterotonics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Blood loss 1000 mL or more after delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.42, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.44, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Third stage greater than 30 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [0.88, 7.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean blood loss (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐99.13 [‐181.40, ‐16.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maternal haemoglobin concentration (Hb) &lt; 7 g/dL 24‐48 hours PP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.18, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mean length of third stage (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.61 [‐9.06, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Manual removal of the placenta <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.89, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oxytocin versus no uterotonics or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001808-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oxytocin versus no uterotonics or placebo‐subgroup analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood loss 500 mL or more after delivery; active v. expectant management <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Active management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.22, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Expectant management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IV oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.21, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IM oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.46, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxytocin dose &lt; 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.24, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oxytocin dose 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.47, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Need for additional uterotonics; active v. expectant management <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Active management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.26, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Expectant management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.42, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for additional uterotonics; IM v. IV oxytocin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 IV oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 IM oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oxytocin dose &lt; 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.22, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Oxytocin dose 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.33, 0.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oxytocin versus no uterotonics or placebo‐subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001808-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oxytocin versus ergot alkaloids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood loss 500 mL or more after delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Need for additional uterotonics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.43, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Blood loss 1000 mL or more after delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.63, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.34, 5.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Third stage &gt; 30 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [1.63, 13.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Diastolic blood pressure &gt; 100 mm Hg between delivery of the baby and discharge from the labour ward <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.04, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mean blood loss (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.97 [‐43.70, 15.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mean length of third stage (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.44, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Manual removal of the placenta <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.39, 3.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Vomiting between delivery of the baby and discharge from the labour ward <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.05, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Headaches between delivery of the baby and discharge from the labour ward <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.03, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oxytocin versus ergot alkaloids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001808-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oxytocin versus ergot alkaloids‐‐subgroup analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood loss 500 mL or more after delivery; active v. expectant management <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.60, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Active management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.47, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Expectant management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.61, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IM oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.48, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IV oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.56, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxytocin dose &lt; 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.46, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oxytocin dose 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.54, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Need for additional uterotonics; active v. expectant management <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.48, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Active management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.40, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Expectant management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.57, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for additional uterotonics; IM v. IV oxytocin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.41, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 IM oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.47, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 IV oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.13, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.41, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oxytocin dose &lt; 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.18, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Oxytocin dose 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.42, 3.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oxytocin versus ergot alkaloids‐‐subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001808-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oxytocin + ergometrine versus ergot alkaloids</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood loss 500 mL or more after delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.20, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Manual removal of the placenta <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.31, 3.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean blood loss (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>61.0 [‐0.90, 122.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Maternal all‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oxytocin + ergometrine versus ergot alkaloids</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001808-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Oxytocin + ergometrine versus ergot alkaloids‐‐subgroup analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood loss 500 mL or more after delivery; active v. expectant management <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.15, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Active management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.15, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Expectant management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.20, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IM oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.20, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IV oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Oxytocin + ergometrine versus ergot alkaloids‐‐subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001808-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Oxytocin versus no uterotonics or placebo‐‐subgroup analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood loss 500 mL or more after delivery; active v. expectant management <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Active management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.22, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Expectant management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Blood loss 500 mL or more after delivery; IM v. IV oxytocin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IV oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.21, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IM oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.46, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Blood loss 500 mL or more after delivery; oxytocin dose &lt; 10 IU v. 10 IU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxytocin dose &lt; 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.24, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oxytocin dose 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.47, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Need for additional uterotonics; active v. expectant management <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Active management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.26, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Expectant management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.42, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Need for additional uterotonics; IM v. IV oxytocin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 IV oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 IM oxytocin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Need for additional uterotonics; oxytocin dose &lt; 10 IU v. 10 IU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.36, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oxytocin dose &lt; 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.22, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Oxytocin dose 10 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.33, 0.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Oxytocin versus no uterotonics or placebo‐‐subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001808.pub3/references#CD001808-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001808.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001808-note-0019">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001808-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001808-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001808-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001808-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001808-note-0006">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD001808-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD001808-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD001808-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001808-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001808-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001808-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001808\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001808\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001808\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001808\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001808\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001808.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001808.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001808.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001808.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001808.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715626729"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001808.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715626736"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001808.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8bb3781b9371',t:'MTc0MDcxNTYyNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 